<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id>
<journal-title>Frontiers in Immunology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Immunol.</abbrev-journal-title>
<issn pub-type="epub">1664-3224</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fimmu.2025.1625437</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Immunology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Distinct NK cell function and gene expression in children with acute lymphoblastic leukemia in remission before and after acute exercise: an exploratory study</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes" corresp="yes">
<name>
<surname>Plaza-Florido</surname>
<given-names>Abel</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<xref ref-type="author-notes" rid="fn003">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/584699/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Perlsteyn</surname>
<given-names>Martin</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn003">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/3095192/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Haddad</surname>
<given-names>Fadia</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cooper</surname>
<given-names>Dan M.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2334996/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bar-Yoseph</surname>
<given-names>Ronen</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lucia</surname>
<given-names>Alejandro</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/513299/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Radom-Aizik</surname>
<given-names>Shlomit</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Research Center for Exercise Medicine and Sleep/Pediatric Exercise and Genomics Research Center, Department of Pediatrics, School of Medicine, University of California Irvine</institution>, <addr-line>Irvine, CA</addr-line>,&#xa0;<country>United States</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Institute for Clinical Translational Science (ICTS), University of California Irvine</institution>, <addr-line>Irvine, CA</addr-line>,&#xa0;<country>United States</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Pediatric Pulmonary Institute, Ruth Rappaport Children&#x2019;s Hospital</institution>, <addr-line>Haifa</addr-line>,&#xa0;<country>Israel</country>
</aff>
<aff id="aff4">
<sup>4</sup>
<institution>Department of Sport Sciences, Faculty of Medicine, Health and Sports, Universidad Europea de Madrid</institution>, <addr-line>Madrid</addr-line>,&#xa0;<country>Spain</country>
</aff>
<aff id="aff5">
<sup>5</sup>
<institution>Research Institute of the Hospital 12 de Octubre (&#x2018;imas12&#x2019;)</institution>, <addr-line>Madrid</addr-line>,&#xa0;<country>Spain</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Priscilla Brebi, University of La Frontera, Chile</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: David B. Bartlett, Duke University, United States</p>
<p>Adan Gallardo Rodriguez, Navy Medical Center, Mexico</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Shlomit Radom-Aizik, <email xlink:href="mailto:saizik@hs.uci.edu">saizik@hs.uci.edu</email>; Abel Plaza-Florido, <email xlink:href="mailto:aplazafl@hs.uci.edu">aplazafl@hs.uci.edu</email>
</p>
</fn>
<fn fn-type="equal" id="fn003">
<p>&#x2020;These authors have contributed equally to this work and share first authorship</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>13</day>
<month>08</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="collection">
<year>2025</year>
</pub-date>
<volume>16</volume>
<elocation-id>1625437</elocation-id>
<history>
<date date-type="received">
<day>08</day>
<month>05</month>
<year>2025</year>
</date>
<date date-type="accepted">
<day>14</day>
<month>07</month>
<year>2025</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2025 Plaza-Florido, Perlsteyn, Haddad, Cooper, Bar-Yoseph, Lucia and Radom-Aizik.</copyright-statement>
<copyright-year>2025</copyright-year>
<copyright-holder>Plaza-Florido, Perlsteyn, Haddad, Cooper, Bar-Yoseph, Lucia and Radom-Aizik</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<sec>
<title>Background</title>
<p>Brief bouts of exercise mobilize natural killer (NK) cells and influence their function and gene expression in adults. However, little is known about these effects in children with acute lymphoblastic leukemia (ALL) in remission. This study investigated the effect of acute exercise on NK gene expression and cytotoxic activity (NKCA) in children with ALL in remission.</p>
</sec>
<sec>
<title>Methods</title>
<p>Nine B-cell ALL children in remission and 9 age- and sex-matched healthy controls (14.8 &#xb1; 1 and 15 &#xb1; 1 y/o, respectively; 2 girls per group) performed an acute exercise session consisting of eight 2-min bouts of cycle ergometry at 60% of peak work rate (71 &#xb1; 2% of peak oxygen uptake) interspersed with 1-min rest intervals. Circulating NK-cell gene expression profile (RNA-seq) and NKCA (<italic>in vitro</italic> assay) were studied before and after the exercise session.</p>
</sec>
<sec>
<title>Results</title>
<p>At baseline, 284 genes were differently expressed in children with ALL compared to controls, and 179 genes were differently altered by acute exercise in the ALL group (p&lt;0.01). At baseline, nine gene pathways related to NK cell function were affected, while following exercise, 28 pathways associated with inflammatory response and cancer were impacted (FDR&lt;0.05). NKCA following IL-2 stimulation was lower both at baseline (p&lt;0.05) and after exercise (p=0.09) in ALL compared to controls. The impaired activity was partially mitigated following exercise but remained lower in ALL compared to controls.</p>
</sec>
<sec>
<title>Conclusions</title>
<p>Acute exercise may improve NK cell function in ALL children in remission and has the potential to be used as adjunctive therapy in ALL. The differential gene expression response to exercise suggests that NK cells in ALL may adopt a different molecular strategy to fight infections or tumors.</p>
</sec>
</abstract>
<kwd-group>
<kwd>fitness</kwd>
<kwd>physical activity</kwd>
<kwd>omics</kwd>
<kwd>immune function</kwd>
<kwd>cancer</kwd>
</kwd-group>
<counts>
<fig-count count="5"/>
<table-count count="3"/>
<equation-count count="0"/>
<ref-count count="70"/>
<page-count count="13"/>
<word-count count="6493"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-in-acceptance</meta-name>
<meta-value>Inflammation</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<label>1</label>
<title>Introduction</title>
<p>Acute lymphoblastic leukemia (ALL) is the most common cancer of children and adolescents, with an overall survival rate of 90% in western societies attributed to medical advances (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>). Yet, survivors of this malignancy have impaired physical and immune functions (<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B4">4</xref>) and an elevated susceptibility to developing distinct secondary cancers later in life (<xref ref-type="bibr" rid="B5">5</xref>), as well as accelerated cellular aging and chronic inflammation (<xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B7">7</xref>). Natural killer cells (NK), a type of lymphocyte, play important roles in innate immunity and serve as a first line of defense against pathogens and nascent tumors such as leukemias or lymphomas (<xref ref-type="bibr" rid="B8">8</xref>). NK cells show a lower cytotoxic capacity in children with B-cell ALL compared to their healthy peers (<xref ref-type="bibr" rid="B9">9</xref>&#x2013;<xref ref-type="bibr" rid="B12">12</xref>). Additionally, the percentage of NK cells in the bone marrow was found to be a prognostic factor in pediatric B- and T-cell ALL, with B-cell ALL (accounting for nearly 90% of cases) (<xref ref-type="bibr" rid="B13">13</xref>). While tyrosine kinase inhibitors (TKIs) improve survival in pediatric B-cell ALL (<xref ref-type="bibr" rid="B14">14</xref>), they can also modulate NK cell effector function (<xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B16">16</xref>). Thus, both the disease <italic>per se</italic> and its treatments can impact NK cell function. Significant progress has been made in treating ALL; nevertheless, many children suffer relapses despite these advances. There is growing data showing that lifestyle factors, specifically levels of physical activity, can have measurable and substantial impacts on how well patients with a variety of cancers respond to treatment (<xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B18">18</xref>). Physical activity can exert antitumorigenic effects (<xref ref-type="bibr" rid="B17">17</xref>) while also reducing chronic inflammation and improving physical function in survivors of pediatric ALL (<xref ref-type="bibr" rid="B19">19</xref>). In adults, NK cells typically show a biphasic response to a single bout of acute exercise (e.g., &#x2265; 20-60&#x2009;min of cycling or running at moderate intensities) (<xref ref-type="bibr" rid="B17">17</xref>). Thus, an abrupt (i.e., several-fold above baseline) lymphocytosis, including NK cells, occurs during an acute exercise bout and immediately after, with a transient lymphopenia during subsequent recovery wherein previously mobilized cells are redeployed to target tissues (<xref ref-type="bibr" rid="B17">17</xref>).</p>
<p>A single bout of acute exercise has also shown to transiently increase the number of circulating NK cells in healthy children (<xref ref-type="bibr" rid="B20">20</xref>, <xref ref-type="bibr" rid="B21">21</xref>). Exercise training can increase immune surveillance and might eventually result in higher immune infiltrates into tumors and, potentially, in delayed cancer growth (<xref ref-type="bibr" rid="B17">17</xref>). Additionally, there is meta-analytical evidence that a single bout of acute exercise increases natural killer cell cytotoxic activity (NKCA) <italic>in vitro</italic> during 1&#x2013;2 hours post-exercise in healthy adults (<xref ref-type="bibr" rid="B22">22</xref>), but to our knowledge, this remains to be corroborated in the pediatric population. Furthermore, the molecular mechanisms underlying the NK cell responses to exercise need to be explored in depth using state-of-the-art omics technologies (<xref ref-type="bibr" rid="B23">23</xref>). In this context, it has been reported that NK cells mobilized into the circulation with a single bout of acute exercise show an anti-tumor transcriptomic profile in healthy adults (<xref ref-type="bibr" rid="B24">24</xref>, <xref ref-type="bibr" rid="B25">25</xref>). To the best of our knowledge, the genomic and functional responses of NK-cell to acute exercise in children who are in remission of ALL remain unknown.</p>
<p>This study assessed the effect of an acute exercise session on NK cell genomic response (RNA-seq) and function (NKCA, as assessed <italic>in vitro</italic>) in adolescents with B-cell ALL in remission, compared to age- and sex-matched controls with no history of cancer. Our group&#x2019;s extensive experience in exercise testing in children and adolescents was essential in ensuring that the exercise input, namely, the relative work intensity and duration, were comparable in both groups. We hypothesized that the NK cells from the participants with B-cell ALL in remission will exhibit a distinct gene expression pattern and functional responses to acute exercise compared to healthy controls. This differential response may reflect an impaired ability to defend against infections and malignancies.</p>
</sec>
<sec id="s2">
<label>2</label>
<title>Methods</title>
<sec id="s2_1">
<label>2.1</label>
<title>Participants and study design</title>
<p>Nine B-cell ALL children in remission stage and nine sex- and age-matched healthy controls with no history of cancer (14.8 &#xb1; 1 and 15 &#xb1; 1 y/o, respectively; two girls per group) completed two study visits at UC Irvine&#x2019;s Pediatric Exercise and Genomics Research Center. Exclusion criteria included: i) children with ALL who were unable to exercise or who had accompanying chronic illnesses that would preclude their participation in the study (e.g., cardiovascular diseases) and ii) body mass index (BMI) percentile &#x2265;95th. The Institutional Review Board at the UC Irvine approved the study, and written, informed assent and consent were obtained from all participants and their legal guardians upon enrollment. Participants arrived at the Pediatric Exercise and Genomics Research Center on two separate occasions. The first visit included anthropometric measurements and a standardized aerobic fitness assessment (cardiopulmonary exercise testing &#x2013; CPET). The second visit included an exercise challenge designed to mimic typical exercise patterns in children. This consisted of eight 2-min bouts of vigorous intensity exercise on a cycle ergometer at a constant work rate (see section 2.3. for details). Blood was drawn before and immediately after the exercise session. Complete blood counts (CBC) and plasma lactate levels were measured. Peripheral blood mononuclear cells (PBMCs) were isolated, and an NKCA assay was performed. NK cells were isolated from PBMCs using a negative magnetic cell separation method and analyzed for gene expression levels using RNA-seq.</p>
</sec>
<sec id="s2_2">
<label>2.2</label>
<title>Visit 1: anthropometric and cardiopulmonary exercise testing</title>
<p>Standard calibrated scales and stadiometers were used to determine height and body mass. Cardiopulmonary exercise testing (CPET) was done on the first visit using a ramp-type progressive exercise protocol that has been used extensively in children, adolescents, and young adults in our laboratory (<xref ref-type="bibr" rid="B24">24</xref>, <xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B27">27</xref>). The participants pedaled on an electronically braked cycle ergometer (VIAsprint<sup>&#xae;</sup> 150p, Ergoline GmbH; Bitz, Germany) until they reached the limit of tolerance indicated either by the participants themselves or by the assessment of the experienced laboratory staff and faculty. Gas exchange was measured breath-by-breath using a Sensor Medics system (Vmax Encore 229; Yorba Linda, CA, USA). Participants were vigorously encouraged to continue pedaling during the high-intensity phases of the test. Peak oxygen uptake (<inline-formula>
<mml:math display="inline" id="im1">
<mml:mover accent="true">
<mml:mi>V</mml:mi>
<mml:mo>&#x2d9;</mml:mo>
</mml:mover>
</mml:math>
</inline-formula>O<sub>2</sub>peak) was determined as the highest 20-s rolling average in the last minute of CPET.</p>
</sec>
<sec id="s2_3">
<label>2.3</label>
<title>Visit 2: acute exercise protocol with blood draws</title>
<p>Participants arrived at the laboratory between 7:30&#x2013;8:30 a.m. after an overnight fast. An indwelling catheter was inserted into the antecubital vein. A baseline sample was taken 30 min after the placement of the catheter and before the onset of exercise. Participants then completed an acute exercise session on a cycle ergometer consisting of eight 2-minute bouts at 60% of the peak work rate achieved in CPET, interspersed with 1-minute rest periods. Gas exchange was measured breath by breath using a metabolic cart. Additional blood samples were obtained immediately after exercise (within one minute). CBCs were obtained by standard methods from the clinical hematology laboratory. Plasma lactate (venous) was measured before and after exercise using an YSI 2300 STAT Plus&#x2122; Glucose &amp; Lactate Analyzer (Marshall Scientific; Hampton, NH, USA).</p>
</sec>
<sec id="s2_4">
<label>2.4</label>
<title>Peripheral blood mononuclear cells isolation and NK cytotoxicity assay</title>
<p>PBMCs were isolated from 20mL of EDTA-treated blood using OptiPrep<sup>&#xae;</sup> Density Gradient Medium (Sigma-Aldrich; St. Louis, MO, USA) and were washed with PBS (calcium- and magnesium-free) and resuspended in 5mL of Complete Medium (RPMI with 1% penicillin-streptomycin and 10% fetal bovine serum). Cell concentration was adjusted to 5 x 10<sup>6</sup>/mL and counted using a Countess II (Invitrogen; Carlsbad, CA, USA). An aliquot of PBMCs containing NK cells was used as effector cells in the NKCA, another aliquot was used to determine the NK cell proportion by flow cytometry, where NK cells were defined as CD3-negative and CD56-positive. The remaining PBMCs were used to isolate NK cells for RNA extraction.</p>
<p>Seven children with ALL in remission and seven sex and age-matched controls with sufficient PBMC yield were included in the NKCA analysis. The NKTEST<sup>&#xae;</sup> kit from Glycotope Biotechnology (Allele Biotechnology, San Diego, CA) was used to evaluate NKCA following the kit instructions. This kit quantifies NKCA using 10,000 green fluorescent K562 target cells incubated with PBMCs as effector cells at ratios of 0:1 and 25:1 for four hours at 37&#xb0;C. In these NKTEST assays, effector cells were the PBMCs, peripheral blood mononucleated cells containing NK cells, monocytes, and T-lymphocytes. The 0:1 ratio (target cells only) served as a negative control to account for spontaneous cell death during the 4 hours incubation at 37&#xb0;C. Specific NKCA was calculated by subtracting the control activity from the test sample activity at 25:1. To assess the effect of IL-2 stimulation, effector cells were incubated with interleukin (IL)-2 at 60 units/mL, a concentration known to increase NK cell cytotoxic activity (<xref ref-type="bibr" rid="B28">28</xref>). The goal was to compare IL-2&#x2013;induced cytotoxic activity between children with ALL in remission and healthy controls. Post-incubation, killed target cells were identified by red DNA staining and analyzed via flow cytometry (BD Accuri C6 flow cytometer). NKCA was reported as the percentage of red-stained cells relative to the total green-stained cells. The NKCA assays were performed in duplicates.</p>
</sec>
<sec id="s2_5">
<label>2.5</label>
<title>NK cell isolation and RNA sequencing</title>
<p>NK cells were isolated from PBMCs using the Miltenyi Biotec NK Cell Isolation Kit (Cat# 130-092-657; Miltenyi Biotech, Bergisch Gladbach, Germany) and the AutoMACS Pro Separator. Non-NK cells were magnetically labeled and depleted (negative selection) to achieve high-purity NK cell preps. NK cell purity was determined by flow cytometry, averaging 88% at baseline (range 80-93%) and 92% (range 88-95%) at peak exercise. The isolated NK cells were washed with PBS and resuspended in Trizol, and RNA was extracted using the Trizol method. The RNA was then treated with DNase and purified using Zymo RNA cleanup columns. RNA concentration was measured with a Nanovue spectrophotometer, and RNA integrity was assessed using an Agilent Bioanalyzer, with RIN scores averaging above 8.0.</p>
<p>Library preparations, RNA sequencing, and data processing were performed at the UC Irvine&#x2019;s High Throughput Facility, with whole transcriptome sequencing conducted on an Illumina HiSeq platform (~200M X2 paired-end 100 bp reads). The reads for whole transcriptome sequencing were downloaded and analyzed using FASTQC (v.0.11.2), then trimmed using Trimmomatic (v.0.32) with Illumina TruSeq adapter sequences, PHRED quality score 15 and minimum length 20 bases. The trimmed reads were aligned to the Human hg19 reference genome with transcriptome annotation and post-processed using Tophat2 (v.2.0.12), Bowtie2 (v.2.2.3), and Samtools (v.0.1.19). Expression levels were quantified both with fragment per kilobase per million mapped reads using Cufflinks (v.2.1.1) and with raw counts using HTSeq (v.0.6.1p1.) (GEO accession number GSE272928).</p>
</sec>
<sec id="s2_6">
<label>2.6</label>
<title>Data analyses</title>
<p>An unpaired Student&#x2019;s <italic>t-</italic>test for between-group comparisons at baseline of anthropometric variables, cardiorespiratory fitness, and exercise intensity was performed. A repeated-measures two-way (group, time) analysis of variance (ANOVA) was used to examine differences for those variables (i.e., lactate, NK cell proportions) pre-post exercise. Non-parametric Wilcoxon and Mann-Whitney U tests were performed to explore NKCA with and without IL-2 stimulation differences in response to exercise. Results were considered statistically significant at p&lt;0.05.</p>
<p>Differential gene expression analysis was performed using DESeq2 (v.1.38.3). Paired design was used to account for samples from the same patient. Multifactor design with interaction terms was applied for group differences, and a p-value cut-off of 0.01 was considered statistically significant. Canonical pathways and interactive network analyses were performed using QIAGEN&#x2019;s Ingenuity<sup>&#xae;</sup> Pathway Analysis (IPA<sup>&#xae;</sup>) (QIAGEN, Redwood City, CA, USA; <ext-link ext-link-type="uri" xlink:href="http://www.qiagen.com/ingenuity">www.qiagen.com/ingenuity</ext-link>) (<xref ref-type="bibr" rid="B29">29</xref>). Canonical pathways with a false discovery rate (FDR) &lt;0.05 were considered statistically significant. The calculation of activation Z-scores in IPA is described elsewhere (<xref ref-type="bibr" rid="B29">29</xref>). In addition, interactive gene network analysis was performed based on the connectivity among genes altered by exercise and the top-IPA network with the cut-point of 35 molecules (default settings) and the highest IPA score was presented (<xref ref-type="bibr" rid="B30">30</xref>).</p>
</sec>
</sec>
<sec id="s3" sec-type="results">
<label>3</label>
<title>Results</title>
<p>
<xref ref-type="table" rid="T1">
<bold>Table&#xa0;1</bold>
</xref> shows anthropometric characteristics and VO<sub>2</sub>peak in children with ALL in remission and controls, with no statistically significant difference between the two groups (P&gt;0.05). Relative exercise intensity of the exercise session (percentage of peak work rate and peak heart rate) was similar in ALL children in remission and controls (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1A</bold>
</xref>). Blood lactate concentration (a surrogate for intense effort) and NK cell proportions increased significantly following the acute exercise session in both groups (P=0.001 for time effect in ALL and controls), with no significant group by time interaction effect (P=0.296 and 0.263 respectively) (<xref ref-type="fig" rid="f1">
<bold>Figures&#xa0;1B, C</bold>
</xref>). Both ALL and control groups increased NKCA following exercise (P=0.02 in both groups) with no significant differences between groups (P=0.33) (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2A</bold>
</xref>). At baseline, NK cells from ALL children in remission exhibited lower NKCA following IL-2 stimulation compared to controls (average 62% <italic>vs</italic>. 143%, respectively; P=0.001), and after exercise, NKCA increased in both groups but remained lower in ALL compared to controls, (average 80% <italic>vs</italic>. 155%, P=0.09, [<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2B</bold>
</xref>]).</p>
<table-wrap id="T1" position="float">
<label>Table&#xa0;1</label>
<caption>
<p>Anthropometric variables and fitness.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="top" align="left">Variable</th>
<th valign="top" align="center">ALL (N=9; 2 female)</th>
<th valign="top" align="center">Controls (N=9; 2 female)</th>
<th valign="top" align="center">P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">Age (years)</td>
<td valign="top" align="center">14.8 &#xb1; 0.8</td>
<td valign="top" align="center">15.0 &#xb1; 0.9</td>
<td valign="top" align="center">0.51</td>
</tr>
<tr>
<td valign="top" align="left">Height (cm)</td>
<td valign="top" align="center">160.7 &#xb1; 4.0</td>
<td valign="top" align="center">165.9 &#xb1; 4.8</td>
<td valign="top" align="center">0.30</td>
</tr>
<tr>
<td valign="top" align="left">Body mass (kg)</td>
<td valign="top" align="center">56.8 &#xb1; 3.7</td>
<td valign="top" align="center">60.8 &#xb1; 6.2</td>
<td valign="top" align="center">0.53</td>
</tr>
<tr>
<td valign="top" align="left">BMI (percentile)</td>
<td valign="top" align="center">63.6 &#xb1; 9.9</td>
<td valign="top" align="center">54.4 &#xb1; 11.6</td>
<td valign="top" align="center">0.88</td>
</tr>
<tr>
<td valign="top" align="left">VO<sub>2</sub>peak (mL/kg/min)</td>
<td valign="top" align="center">41.0 &#xb1; 3.3</td>
<td valign="top" align="center">47.1 &#xb1; 3.2</td>
<td valign="top" align="center">0.20</td>
</tr>
<tr>
<td valign="top" align="left">Work rate peak (Watts)</td>
<td valign="top" align="center">150.0 &#xb1; 12.8</td>
<td valign="top" align="center">192.8 &#xb1; 2.8</td>
<td valign="top" align="center">0.13</td>
</tr>
<tr>
<td valign="top" align="left">Heart rate peak (bpm)</td>
<td valign="top" align="center">196.1 &#xb1; 4.7</td>
<td valign="top" align="center">197.3 &#xb1; 2.8</td>
<td valign="top" align="center">0.84</td>
</tr>
<tr>
<td valign="top" align="left">Peak respiratory Exchange Ratio (VCO<sub>2</sub>/VO<sub>2</sub>)</td>
<td valign="top" align="center">1.26 &#xb1; 0.04</td>
<td valign="top" align="center">1.25 &#xb1; 0.03</td>
<td valign="top" align="center">0.85</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>Values are means &#xb1; SE. ALL, acute lymphoblastic leukemia; BMI, body mass index; bpm, beats per minute; VCO<sub>2</sub>/VO<sub>2,</sub> ratio between the volume of carbon dioxide and oxygen consumed; VO2peak, peak oxygen consumption. No significant between-group differences were found.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>Relative exercise intensity of the exercise session was similar in ALL children in remission and controls <bold>(A)</bold> Blood lactate <bold>(B)</bold> concentration and NK cell proportions <bold>(C)</bold> increased significantly following the acute exercise session in both groups, with no significant group by time interaction effect. Data are mean &#xb1; SD and individual data values. *<italic>p</italic> &lt;&#x2009;0.05.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-16-1625437-g001.tif">
<alt-text content-type="machine-generated">Bar graphs comparing control and ALL groups, split into three panels. A) Percentage of peak exercise shows similar work and heart rates between groups. B) Lactate levels (mmol/L) demonstrate significant increases post-intervention in both groups. C) NK cells as a percentage of PBMCs show a significant post-intervention increase in both groups. Statistical significance is indicated by asterisks.</alt-text>
</graphic>
</fig>
<fig id="f2" position="float">
<label>Figure&#xa0;2</label>
<caption>
<p>
<bold>(A)</bold> Significant increase in NK cells killing activity in response to exercise in both control and children with ALL in remission. The % increase in NKCA in response to exercise was similar in both groups. <bold>(B)</bold> There was a significant increase in NK cell killing activity in response to IL-2 stimulation in both the control group and children with ALL in remission. However, the percentage increase in NKCA in response to IL-2 stimulation was significantly lower in children with ALL in remission compared to the control group, both at baseline and after exercise. Data are median, interquartile range, and individual values. **<italic>p</italic> &lt;&#x2009;0.05; *<italic>p</italic> &lt;&#x2009;0.1. Abbreviations: ALL, acute lymphoblastic leukemia; CON, control; NK, natural killer; NKCA, NK-cell cytotoxic activity (as assessed <italic>in vitro</italic>).</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-16-1625437-g002.tif">
<alt-text content-type="machine-generated">Bar graphs showing natural killer cell activity (NKCA). Panel A: Percentage of dead cells in Control and ALL groups, both pre and post, with significant differences indicated by asterisks. Panel B: Percentage change in NKCA in response to IL2 for the same groups, with significant changes noted. Control bars are light blue and ALL bars are dark blue. Error bars represent variability within each group.</alt-text>
</graphic>
</fig>
<p>At baseline, 284 genes were differentially expressed in NK cells of children with ALL in remission compared to controls (160 genes down-regulated and 124 up-regulated; log<sub>2</sub>FC ranged from &#x2013;5.56 to 6.19, p&#x2009;&lt;&#x2009;0.01 [<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Table S1</bold>
</xref>). These genes were enriched in 9 gene pathways related to immune function (e.g., hematopoiesis from multipotent stem cells, Th1 and Th2 Activation Pathway, transcriptional regulation by RUNX2; p&#x2009;&lt;&#x2009;0.01, <xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3</bold>
</xref>). Two pathways (&#x201c;Th2 Pathway&#x201d; and &#x201c;Regulation of the Epithelial Mesenchymal Transition by Growth Factors Pathway&#x201d;) were inhibited in NK cells from children with ALL in remission compared to controls (Z-score values of activation -0.82 and -0.33 respectively), while two pathways (&#x201c;Epithelial Adherens Junction Signaling&#x201d; and &#x201c;Transcriptional regulation by RUNX2&#x201d;) were activated in the former (Z-score values of activation 1.13 and 0.45 respectively) (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3</bold>
</xref>). Several genes involved in IL-2 family signaling (<italic>HAVCR2</italic>, <italic>IL3RA</italic>, <italic>INPP5J</italic>), Glucocorticoid Receptor Signaling (<italic>ANXA1</italic>, <italic>AR</italic>, <italic>HLA-DQA1</italic>, <italic>IFNLR1</italic>, <italic>IL3RA</italic>, <italic>IL4</italic>, <italic>KRT1</italic>, <italic>MMP1</italic>, <italic>MT-ND3</italic>, <italic>MT-ND6</italic>, <italic>RARB</italic>, <italic>SDHA</italic>), PI3K/AKT Signaling (<italic>IFNLR1</italic>, <italic>IL3RA</italic>, <italic>INPP5J</italic>, <italic>ITGAD</italic>, <italic>YWHAQ</italic>), and molecular mechanisms of cancer (<italic>ADGRA3</italic>, <italic>C5AR2</italic>, <italic>CDKN2C</italic>, <italic>CTNNA1</italic>, <italic>GPR173</italic>, <italic>GPR183</italic>, <italic>IFNLR1</italic>, <italic>IL3RA</italic>, <italic>ITGAD</italic>, <italic>MMP1</italic>, <italic>PTGDR2</italic>, <italic>PTGER3</italic>, <italic>RBL1</italic>) were differently expressed in NK cells from children with ALL in remission compared to controls (<xref ref-type="table" rid="T2">
<bold>Table&#xa0;2</bold>
</xref>, <xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Tables S1</bold>
</xref>, <xref ref-type="supplementary-material" rid="SM1">
<bold>S2</bold>
</xref>).</p>
<fig id="f3" position="float">
<label>Figure&#xa0;3</label>
<caption>
<p>Canonical pathways showing different gene expression patterns at baseline in children with acute lymphoblastic leukemia in remission compared to controls. The blue color represents inhibition and orange activation, and the gray effect is not predicted. The x-axis reflects the p-value, while the y-axis corresponds to the names of the pathways.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-16-1625437-g003.tif">
<alt-text content-type="machine-generated">Bubble chart depicting pathways and their significance. Pathways are plotted against the negative log of p-values. Bubbles vary in size indicating the number of overlapping genes and color indicating activity patterns: blue for negative, orange for positive, and grey for zero value. Pathways include Osteoarthritis Pathway and Th2 Pathway.</alt-text>
</graphic>
</fig>
<table-wrap id="T2" position="float">
<label>Table&#xa0;2</label>
<caption>
<p>Selected genes showing differential baseline expression in NK cells from B-cell acute lymphoblastic leukemia (ALL) patients compared to controls.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="top" align="left">Gene pathways</th>
<th valign="top" align="left">Genes identified in the pathway (log<sub>2</sub>FC ALL <italic>vs</italic> Control)</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">IL-2 family signaling</td>
<td valign="top" align="left">
<italic>HAVCR2</italic> (0.48), <italic>IL3RA</italic> (-1.15), <italic>INPP5J</italic> (-2.62)</td>
</tr>
<tr>
<td valign="top" align="left">Glucocorticoid Receptor Signaling</td>
<td valign="top" align="left">
<italic>ANXA1</italic> (0.44), <italic>AR</italic> (-1.56), <italic>HLA-DQA1</italic> (-1.24), <italic>IFNLR1</italic> (1.69), <italic>IL3RA</italic> (-1.15), <italic>IL4</italic> (-3.83), <italic>KRT1</italic> (0-1.53), <italic>MMP1</italic> (3.45), <italic>MT-ND3</italic> (-0.54), <italic>MT-ND6</italic> (-1.06), <italic>RARB</italic> (2.34), <italic>SDHA</italic> (0.20)</td>
</tr>
<tr>
<td valign="top" align="left">PI3K/AKT Signaling</td>
<td valign="top" align="left">
<italic>IFNLR1</italic> (1.69), <italic>IL3RA</italic> (-1.15), <italic>INPP5J</italic> (-2.62), <italic>ITGAD</italic> (1.45), <italic>YWHAQ</italic> (0.25)</td>
</tr>
<tr>
<td valign="top" align="left">Molecular mechanisms of cancer</td>
<td valign="top" align="left">
<italic>ADGRA3</italic> (-0.84), <italic>C5AR2</italic> (-1.06), <italic>CDKN2C</italic> (0.49), <italic>CTNNA1</italic> (0.62), <italic>GPR173</italic> (-1.00), <italic>GPR183</italic> (-0.75), <italic>IFNLR1</italic> (1.69), <italic>IL3RA</italic> (-1.15), <italic>ITGAD</italic> (1.45), <italic>MMP1</italic> (3.45), <italic>PTGDR2</italic> (-1.12), <italic>PTGER3</italic> (-1.79), <italic>RBL1</italic> (0.35)</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Genes differentially affected by exercise in children with ALL in remission compared to controls [179 genes, log<sub>2</sub>FC values from interaction analyses ranged from -3.62 to 2.35 (163 genes showed negative values and 16 positive values); p&#x2009;&lt;&#x2009;0.01, (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Table S3</bold>
</xref>)] were enriched in 28 gene pathways involved in inflammatory response and cancer disease (e.g., S100 Family Signaling Pathway, TREM1 Signaling, FAK Signaling, Molecular Mechanisms of Cancer, Breast Cancer Regulation by Stathmin1, Pathogen Induced Cytokine Storm Signaling Pathway, Toll-like Receptor Cascades) [FDR&#x2009;&lt;&#x2009;0.05, (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4</bold>
</xref>, <xref ref-type="table" rid="T3">
<bold>Table&#xa0;3</bold>
</xref>)]. These pathways were inhibited by exercise in NK cells from cancer in remission compared to controls (Z-score values of activation ranged from -1.63 to -5.00, except for one pathway, &#x201c;Cellular Effects of Sildenafil,&#x201d; which was activated, Z-score = 3.36) (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4</bold>
</xref>, <xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Table S4</bold>
</xref>). We did not observe a significant gene overlap between baseline differences and exercise effects between groups. The top-IPA gene network (IPA score 46) highlighted molecular functions, such as cellular function and maintenance, hematological system development and function, and inflammatory response differently altered by exercise in children with ALL in remission compared to controls (<xref ref-type="fig" rid="f5">
<bold>Figure&#xa0;5</bold>
</xref>), where <italic>IL1B</italic> gene presented the highest number of connections in this gene network (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Table S5</bold>
</xref>). In addition to the results of interaction analyses (i.e., between-group comparisons; <xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Table&#xa0;3</bold>
</xref>), we reported within-group gene expression changes in children with ALL in remission and controls (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Tables S6</bold>
</xref>, <xref ref-type="supplementary-material" rid="SM1">
<bold>S7</bold>
</xref>, <xref ref-type="supplementary-material" rid="SF1">
<bold>Supplementary Figure S1</bold>
</xref>).</p>
<fig id="f4" position="float">
<label>Figure&#xa0;4</label>
<caption>
<p>Canonical pathways differently altered by acute exercise in children with acute lymphoblastic leukemia in remission compared to controls. The blue color represents inhibition and orange activation, and the gray effect is not predicted. The x-axis reflects the p-value, while the y-axis corresponds to the names of the pathways.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-16-1625437-g004.tif">
<alt-text content-type="machine-generated">Bubble chart displaying various pathways on the Y-axis and the -log(p-value) on the X-axis. Bubbles represent the number of overlapping genes, varying in size. Colors indicate z-scores: blue for negative, orange for positive, gray for zero, and white for no activity.</alt-text>
</graphic>
</fig>
<table-wrap id="T3" position="float">
<label>Table&#xa0;3</label>
<caption>
<p>Selected gene pathways differently altered by exercise in natural killer (NK) cells from children with B-cell acute lymphoblastic leukemia (ALL) in remission compared to controls (FDR&lt;0.05).</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="top" align="left">Gene pathways (number of genes in the pathway)</th>
<th valign="top" align="left">Link to inflammation, NK cell function or cancer</th>
<th valign="top" align="left">Genes identified in the pathway</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell (12 genes)</td>
<td valign="top" align="left">This pathway was considered a therapeutic target for immune-based therapy (<xref ref-type="bibr" rid="B38">38</xref>).</td>
<td valign="top" align="left">
<italic>CD300E, CD300LF, CD34, JAML, LILRA1, LILRA4, LILRA5, LILRA6, LILRB2, LILRB3, LILRB4, TREM1</italic>
</td>
</tr>
<tr>
<td valign="top" align="left">S100 Family Signaling Pathway (20 genes)</td>
<td valign="top" align="left">S100 genes/proteins are involved in tumors&#x2019; development and drug resistance (<xref ref-type="bibr" rid="B40">40</xref>), as well as inflammatory responses and NK cell activation (<xref ref-type="bibr" rid="B43">43</xref>, <xref ref-type="bibr" rid="B45">45</xref>).</td>
<td valign="top" align="left">
<italic>ADGRE1, ADGRE2, ADGRE3, C5AR1, CYBB, FPR1, FPR2, FZD1, GPR162, HCAR2, HCAR3, HTR7, IL1B, MMP17, NCF2, P2RY13, P2RY2, S100A12, S100A9, VIPR1</italic>
</td>
</tr>
<tr>
<td valign="top" align="left">TREM1 Signaling (5 genes)</td>
<td valign="top" align="left">It is involved in acute inflammatory responses against pathogens (<xref ref-type="bibr" rid="B51">51</xref>, <xref ref-type="bibr" rid="B52">52</xref>) and represents an attractive therapeutic target for cancer (<xref ref-type="bibr" rid="B53">53</xref>).</td>
<td valign="top" align="left">
<italic>IL1B, NLRC4, TLR2, TLR8, TREM1</italic>
</td>
</tr>
<tr>
<td valign="top" align="left">FAK Signaling (16 genes)</td>
<td valign="top" align="left">FAK protein promotes tumor growth and metastasis (<xref ref-type="bibr" rid="B66">66</xref>). FAK expression in myeloid cells modulates the recruitment and survival of NK cells within the tumor microenvironment (<xref ref-type="bibr" rid="B66">66</xref>).</td>
<td valign="top" align="left">
<italic>ADGRE1, ADGRE2, ADGRE3, C5AR1, FPR1, FPR2, FZD1, GPR162, HCAR2, HCAR3, HTR7, P2RY13, P2RY2, TRAV8-3, TRGV5, VIPR1</italic>
</td>
</tr>
<tr>
<td valign="top" align="left">Toll-like Receptor Cascades (3 genes)</td>
<td valign="top" align="left">These receptors induce innate immune responses against pathogens, increasing NKCA and cytokine production (<xref ref-type="bibr" rid="B67">67</xref>).</td>
<td valign="top" align="left">
<italic>CD14, TLR2, TLR8</italic>
</td>
</tr>
<tr>
<td valign="top" align="left">Pathogen Induced Cytokine Storm Signaling Pathway (10 genes)</td>
<td valign="top" align="left">The overproduction of cytokines (i.e., cytokine storm) is observed in cancer disease and COVID-19 (<xref ref-type="bibr" rid="B68">68</xref>).</td>
<td valign="top" align="left">
<italic>CLEC7A, CSF2RA, CXCL16, CXCR3, IFNGR2, IL1B, NLRC4, SPI1, TLR2, TLR8</italic>
</td>
</tr>
<tr>
<td valign="top" align="left">Immunogenic Cell Death Signaling Pathway (5 genes)</td>
<td valign="top" align="left">Immunogenic Cell Death can trigger or boost immune responses against cancer (<xref ref-type="bibr" rid="B69">69</xref>).</td>
<td valign="top" align="left">
<italic>FPR1, IFNGR2, IL1B, LRP1, P2RY2</italic>
</td>
</tr>
<tr>
<td valign="top" align="left">G-Protein Coupled Receptor Signaling (14 genes)</td>
<td valign="top" align="left">G protein-coupled receptors might regulate NKCA and cytokine production, while the up-regulation of these proteins was associated with shorter overall survival in patients with acute myeloid leukemia (<xref ref-type="bibr" rid="B70">70</xref>).</td>
<td valign="top" align="left">
<italic>ADGRE1, ADGRE2, ADGRE3, C5AR1, FPR1, FPR2, FZD1, GPR162, HCAR2, HCAR3, HTR7, P2RY13, P2RY2, VIPR1</italic>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>FAK, focal adhesion kinase; NK, Natural killer; NKCA, NK-cell cytotoxic activity; TREM1, Triggering Receptor Expressed on Myeloid Cells 1.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<fig id="f5" position="float">
<label>Figure&#xa0;5</label>
<caption>
<p>
<italic>IL1B</italic> (Interleukin-1beta) was identified as the top-hub gene in the interactive network of the differential NK transcriptome response to acute exercise in children with acute lymphoblastic leukemia in remission compared to controls. The purple color of the nodes indicates negative log<sub>2</sub>FC values in the interaction analyses and the red color positive values. Blue and orange color for molecules indicates predicted inhibition and activation respectively. Molecule shapes and relationship lines are available in IPA&#xae;, QIAGEN Redwood City, <ext-link ext-link-type="uri" xlink:href="http://www.qiagen.com/ingenuity">www.qiagen.com/ingenuity</ext-link>. Solid and dashed lines reflect direct and indirect relationships between molecules. Circles lines show that the molecule interacts with itself (e.g., dimerization). The blue color of the arrows indicates &#x201c;leads to inhibition,&#x201d; orange &#x201c;leads to activation,&#x201d; yellow &#x201c;findings inconsistent with the state downstream molecule,&#x201d; and grey &#x201c;effect not predicted.&#x201d; Please see: <ext-link ext-link-type="uri" xlink:href="https://qiagen.secure.force.com/KnowledgeBase/articles/Basic_Technical_Q_A/Legend">https://qiagen.secure.force.com/KnowledgeBase/articles/Basic_Technical_Q_A/Legend</ext-link> for more details about molecule shapes and relationship.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-16-1625437-g005.tif">
<alt-text content-type="machine-generated">Network diagram illustrating the interactions between various proteins and complexes, centered around IL1B. Lines in different colors and styles denote types of interactions or pathways. Each node is labeled with a protein name, such as ASGR1, CD14, and CREB.</alt-text>
</graphic>
</fig>
</sec>
<sec id="s4" sec-type="discussion">
<label>4</label>
<title>Discussion</title>
<p>The main findings of this study were: i) at baseline and post-exercise, NKCA (<italic>in vitro</italic>) was lower following IL-2 activation in children with ALL in remission compared to controls, and several genes and pathways involved in NK cell function were differently expressed in circulating NK cells between the two groups; ii) an acute exercise session induced a comparable, robust (~two- to threefold) mobilization of NK cells into the peripheral circulation in the two groups; iii) NKCA (without IL-2 activation) following the acute exercise session significantly increased in both groups with no between-group differences; and iv) the immune gene expression pathway response to acute exercise differed between the two groups, as well as the expression of genes involved in inflammation and leukemia.</p>
<p>At baseline, children with ALL in remission exhibited lower NK cell function after IL-2 activation compared to controls. Additionally, we detected several genes that were differently expressed in circulating NK cells between groups (e.g., <italic>HAVCR2</italic>, <italic>IL3RA</italic>, <italic>INPP5J, HLA-DQA1</italic>, <italic>IFNLR1, IL4, IFNLR1, ITGAD</italic>, <italic>ITGB8</italic>), which are involved in key signaling pathways (IL-2 family signaling, glucocorticoid receptor signaling, and PI3K/AKT signaling). These differences may contribute to the decreased NK cell function after IL-2 activation (<xref ref-type="bibr" rid="B31">31</xref>&#x2013;<xref ref-type="bibr" rid="B33">33</xref>). The IL-2 family signaling pathway is crucial for NK cell activation and proliferation. Altered gene expression in this pathway, such as <italic>IL3RA</italic> and <italic>IL4</italic>, may reduce NK cell response to IL-2 in children with ALL in remission (<xref ref-type="bibr" rid="B34">34</xref>). IL4 is a cytokine that can also interact with the glucocorticoid receptor signaling pathway, which exerts immunosuppressive effects that can diminish NK cell function. Additionally, the PI3K/AKT pathway, which is essential for cell survival and growth, can affect NK cell function through gene expression changes, such as <italic>INPP5J</italic>, impacting their survival and activation in response to IL-2. The gene pathway &#x201c;Transcriptional Regulation by RUNX2&#x201d; was activated at baseline in NK cells of ALL in remission compared to controls. It was observed that RUNX2 drives the generation of mature human NK cells (<xref ref-type="bibr" rid="B35">35</xref>) and regulates leukemic cell metabolism and chemotaxis in patients with T-cell ALL (<xref ref-type="bibr" rid="B36">36</xref>). These gene expression differences observed between groups could partially underlie the lower NKCA of ALL in remission compared to controls.</p>
<p>Previous studies in healthy adults have shown that a single bout of acute exercise increases NK cell numbers and NKCA (<xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B22">22</xref>), as well as the expression of genes involved in the NK cell signaling pathway (<xref ref-type="bibr" rid="B24">24</xref>, <xref ref-type="bibr" rid="B25">25</xref>). In our study, NK cell proportions, NKCA, and the expression of NK cell signaling pathways after acute exercise increased in both ALL and control groups in a similar magnitude (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figure S1</bold>
</xref>). Our results could overall suggest that acute exercise transiently improves immunosurveillance in ALL children in remission. Due to the capacity of an acute exercise stimulus to enhance the release of immune cell effectors, it has been suggested that immune cells from blood collected after an acute exercise bout might be used in the future as an adjunctive cell therapy for blood malignancies (<xref ref-type="bibr" rid="B17">17</xref>). Previous targeted-proteomics analyses have shown that regular exercise (16-week training) decreases systemic inflammation in survivors of pediatric B-cell ALL (<xref ref-type="bibr" rid="B19">19</xref>). In our study, an acute exercise bout induced a down-regulation of hundreds of genes and inhibited several gene pathways involved in inflammatory responses (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4</bold>
</xref>) in children with ALL in remission compared to controls (<xref ref-type="table" rid="T3">
<bold>Table&#xa0;3</bold>
</xref>, <xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4</bold>
</xref>). The control group showed a higher expression of genes involved in the antigen processing and presentation pathway in NK cells after exercise (<xref ref-type="bibr" rid="B24">24</xref>, <xref ref-type="bibr" rid="B25">25</xref>), suggesting an improved immunosurveillance (<xref ref-type="bibr" rid="B37">37</xref>). We observed that acute exercise reduced the expression of genes involved in the MHC I-mediated antigen processing and presentation pathway (<italic>ASB13</italic>, <italic>CD14</italic>, <italic>CTSL</italic>, <italic>CYBB</italic>, <italic>NCF2</italic>, <italic>RNF144B</italic>, <italic>S100A9</italic>, <italic>TLR2</italic>, <italic>UBE2E2</italic>) in the NK cells from children with ALL in remission, but not in the controls (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Tables S6</bold>
</xref>, <xref ref-type="supplementary-material" rid="SM1">
<bold>S7</bold>
</xref>). The pathway &#x201c;immunoregulatory interactions between a lymphoid and non-lymphoid cell&#x201d; involves a number of cell surface receptors (e.g., NK cell inhibitory receptors [KIRs] and leukocyte immunoglobulin-like receptors [LILRs]) and cell adhesion molecules that are involved in the regulation of anti-tumor immunity (<ext-link ext-link-type="uri" xlink:href="https://reactome.org/content/detail/R-HSA-198933">https://reactome.org/content/detail/R-HSA-198933</ext-link>). Shen et&#xa0;al. reported that several genes in the aforementioned pathway (highly enriched in all colorectal tumor locations and stages) were associated with survival and cytotoxic lymphocyte infiltration, suggesting this pathway might serve as a therapeutic target for immune-based therapy (<xref ref-type="bibr" rid="B38">38</xref>). In our study, we found that acute bouts of exercise inhibited this pathway in NK cells from children with ALL in remission compared to controls.</p>
<p>The &#x2018;S100 family signaling pathway&#x2019; was inhibited by exercise in the children with ALL in remission compared to controls. S100 genes/proteins (expressed in immune effectors such as CD8<sup>+</sup> T and NK cells) (<xref ref-type="bibr" rid="B39">39</xref>) belong to a family of calcium-binding proteins with important roles in tumors&#x2019; development and drug resistance (<xref ref-type="bibr" rid="B40">40</xref>). Some pro-inflammatory molecules in the S100 family signaling pathway, such as S100A8, S100A9, and S100A12, have been considered targets to improve treatment efficiency in ALL (<xref ref-type="bibr" rid="B41">41</xref>, <xref ref-type="bibr" rid="B42">42</xref>). In our study, the expression of <italic>S100A8</italic>, <italic>S100A9, and S100A12</italic> genes were reduced by acute exercise in the NK cells from the patients in remission, with no change found in their controls (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Tables S6</bold>
</xref>, <xref ref-type="supplementary-material" rid="SM1">
<bold>S7</bold>
</xref>). S100A8, S100A9, and S100A12 interact with toll-like receptors and G protein-coupled receptors [these pathways were differently altered by exercise in ALL in remission compared to controls, (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4</bold>
</xref>, <xref ref-type="table" rid="T3">
<bold>Table&#xa0;3</bold>
</xref>)] to regulate inflammatory responses in innate immune cells (<xref ref-type="bibr" rid="B43">43</xref>, <xref ref-type="bibr" rid="B44">44</xref>), while a higher S100A8 and S100A9 protein expression in NK cells induces their activation (<xref ref-type="bibr" rid="B45">45</xref>). Furthermore, S100A8, S100A9, and S100A12 proteins act as sensors of intracellular Ca<sup>2+</sup> levels (<xref ref-type="bibr" rid="B44">44</xref>), which is important for the mobilization of NK cells as well as for NKCA (<xref ref-type="bibr" rid="B46">46</xref>, <xref ref-type="bibr" rid="B47">47</xref>). The exercise-induced downregulation of the S100 family signaling pathway may reflect a reduction in inflammatory priming of NK cells post-exercise in children with ALL in remission. This may represent a protective mechanism against chronic low-grade inflammation often seen in cancer survivors. Given the involvement of S100A8 and S100A9 in leukemic progression and treatment resistance (<xref ref-type="bibr" rid="B48">48</xref>&#x2013;<xref ref-type="bibr" rid="B50">50</xref>), these molecular changes highlight the possible therapeutic potential of acute exercise in modulating pro-inflammatory mediators in children with ALL in remission.</p>
<p>TREM1 signaling pathway was inhibited by exercise in NK cells of children with ALL in remission compared to controls, and the <italic>TREM1</italic> gene showed one of the highest down-regulation patterns induced by exercise (top-10 log<sub>2</sub>FC values) in the former while it was not altered by exercise in controls (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Tables S6</bold>
</xref>, <xref ref-type="supplementary-material" rid="SM1">
<bold>S7</bold>
</xref>). <italic>TREM1</italic> encodes a transmembrane glycoprotein receptor that is mainly expressed in neutrophils, monocytes, tissue macrophages, and NK cells (<xref ref-type="bibr" rid="B51">51</xref>, <xref ref-type="bibr" rid="B52">52</xref>), which is important for the triggering and amplifying acute inflammatory responses against pathogens (<xref ref-type="bibr" rid="B51">51</xref>, <xref ref-type="bibr" rid="B52">52</xref>). Additionally, a recent study showed that TREM1 plays a role in the inflamed tumor microenvironment, and its inhibition enhances the antitumorigenic effect of anti&#x2013;PD-1 treatment in murine melanoma, representing an attractive therapeutic target for cancer (<xref ref-type="bibr" rid="B53">53</xref>). Interestingly, one study showed that higher physical activity levels were associated with the inhibition of the TREM1 signaling pathway in whole blood from adults with rheumatoid arthritis (<xref ref-type="bibr" rid="B54">54</xref>). Similarly, a 12-month home-based exercise training intervention reduced <italic>TREM1</italic> expression in monocytes, as well as the soluble TREM1 concentration in plasma from adults with intermittent claudication (<xref ref-type="bibr" rid="B55">55</xref>). The reduced TREM1 expression level in NK cells from children with ALL in remissions immediately following an acute bout of exercise may indicate broader anti-inflammatory reprogramming of the immune response, and/or reflect a transient shift in NK cell subpopulations. This overall decrease in circulating TREM1 expression could potentially contribute to reduced systemic inflammation and improved immune regulation. Given TREM1&#x2019;s emerging role in tumor progression and immune escape mechanisms, its modulation by exercise could support improved immune surveillance and enhance responsiveness to immunotherapeutic strategies. These findings offer new insights into how exercise may serve as a non-pharmacological adjunct to restore immune competence in children with ALL in remission.</p>
<p>
<italic>IL1B</italic> could represent an important molecular driver of the differential transcriptome response to exercise observed in the group of children with ALL in remission compared to their controls; however, these gene expression changes may also result from exercise-induced shifts in NK cell subpopulation composition. <italic>IL1B</italic> was reduced after acute exercise in NK cells of children with ALL in remission but not in controls (log2FC -1.68 <italic>vs</italic>. -0.18; p&lt;0.001 and p=0.59 respectively, [<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Tables S6</bold>
</xref>, <xref ref-type="supplementary-material" rid="SM1">
<bold>S7</bold>
</xref>) and it was the gene with the higher number of connections within the interactive gene network enriched in inflammatory response (<xref ref-type="fig" rid="f5">
<bold>Figure&#xa0;5</bold>
</xref>). IL-1&#x3b2; is a well-known pro-inflammatory cytokine (<xref ref-type="bibr" rid="B56">56</xref>), and <italic>IL1B</italic> gene expression levels at diagnosis predict the relapse in children with pre-B-cell ALL (<xref ref-type="bibr" rid="B57">57</xref>). It could be expected a higher expression of <italic>IL1B</italic> gene in NK cells after acute exercise (i.e., inflammatory response), but findings on this topic are inconsistent in PBMCs (<xref ref-type="bibr" rid="B58">58</xref>). For example, circulating IL-1&#x3b2; increased after acute exercise but the latter did not change <italic>IL1B</italic> gene expression in PBMCs from the same healthy young men (<xref ref-type="bibr" rid="B59">59</xref>). It has been reported that IL-1&#x3b2; limited the level of NK cell activation by causing these cells to undergo apoptosis (<xref ref-type="bibr" rid="B60">60</xref>), while we observed that acute exercise reduced the expression of the gene encoding this cytokine in NK cells from children with ALL in remission but not in controls. Future studies should compare the impact of acute exercise on <italic>IL1B</italic> gene and protein expression in different leukocyte populations and types of cancers, as well as long-term exercise interventions, to reveal the clinical implications of these findings. In summary, the NK cell transcriptome profile showed a differential inflammatory response to acute exercise in children with ALL in remission compared to their controls, which could be related to anti-tumor immunity.</p>
<p>The changes in NK cell gene expression following exercise are driven by a complex interplay of hormonal, neural, and cytokine-mediated signals, as well as direct cellular signaling mechanisms. In our study, most of the children with ALL in remission and healthy controls were male. In this regard, it is known that hormonal differences in males and females during growth can affect NK responses to acute exercise with greater responses in the latter (<xref ref-type="bibr" rid="B21">21</xref>). Future studies should expand our findings by considering sex-specific responses. There is also evidence that anti-tumor activity of NK cells may also depend on specific pattern of marginating pools (<xref ref-type="bibr" rid="B61">61</xref>). These changes help to enhance the functional capacity of NK cells and contribute to the overall benefits of exercise on immune health (<xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B18">18</xref>). The current study design cannot elucidate whether the changes induced in the gene expression of circulating NK cells would also apply to those located in the different bodily reservoirs outside the bloodstream (e.g., NK cells attached to the vascular endothelium, or resident in bone marrow or liver) (<xref ref-type="bibr" rid="B24">24</xref>). Additionally, a fixed amount of PBMCs (including NK cells, monocytes, and cytotoxic CD8+ T cells) was used for co-culturing with the target cells to assess specific NKCA. Since acute exercise increases the relative abundance of NK cells, monocytes and cytotoxic CD8+ T cells in peripheral blood and the PBMCs fraction (<xref ref-type="bibr" rid="B17">17</xref>), we cannot determine whether the increased NKCA after exercise is due solely to enhanced NK cell activity, a higher proportion of NK cells, or potential contributions from other cytotoxic subsets such as monocytes and cytotoxic CD8+ T cells. Future studies may employ spectral flow cytometry to characterize NK cell subtypes, monocytes and CD8+ T cells more precisely, plasma proteomics to assess a broad panel of cytokines, single-cell omics approaches (e.g., scRNA-seq, ATAC-seq) to uncover regulatory mechanisms and cellular heterogeneity not captured by bulk RNA-seq. Together, these complementary methods would deepen mechanistic insight into immune cell dynamics in response to acute exercise in children with ALL in remission.</p>
<p>The exercise protocol was identical in both groups in terms of duration and intensity, inducing a similar increase in blood lactate, NK cell proportions, and relative increase in NKCA <italic>in vitro</italic> after exercise. Nevertheless, <italic>in vitro</italic> NKCA may not directly translate to <italic>in vivo</italic> anti-tumor efficacy, particularly in immunocompromised hosts. The distinct immune gene pathway activation pattern in response to exercise found in ALL children in remission suggests that their NK cells might adopt a different molecular strategy to fight against infections or tumors. Our results identify candidate genes and molecular pathways through which exercise may benefit the immune health status. These findings align with NK cell functional data from this study and previous research on inflammatory proteins (<xref ref-type="bibr" rid="B19">19</xref>), supporting exercise as a potential non-pharmacological intervention for children with ALL in remission. We applied a stringent p-value cutoff of 0.01 for RNA-seq differential expression analysis and used false discovery rate (FDR) correction to account for multiple comparisons in canonical pathway analysis, enhancing result reliability. However, the small sample size, determined by feasibility reasons, limits the generalization of our transcriptome findings, which are hypothesis-generating and lay the groundwork for future larger-scale investigations. Additionally, we did not have access to participants&#x2019; electronic medical records and therefore lacked information on B-cell ALL subtypes and treatment regimens. Future exercise studies using larger sample sizes, randomized controlled designs, and multi-omics (including single-cell) analyses (<xref ref-type="bibr" rid="B62">62</xref>&#x2013;<xref ref-type="bibr" rid="B65">65</xref>) are warranted in this and other pediatric cancer-related populations. Understanding the molecular changes induced by exercise can help in designing exercise programs that optimize immune function, particularly for populations with compromised immunity.</p>
</sec>
<sec id="s5" sec-type="conclusions">
<label>5</label>
<title>Conclusions</title>
<p>Distinct immune gene pathway responses to acute exercise were observed in circulating NK cells from B-cell ALL children in remission compared to controls with no history of cancer. Studying the NK-cell genomic response to exercise could thus be helpful in identifying molecular pathways and candidate genes related to impaired NK cell function or differential inflammatory response to physical stress after surviving cancer, which might remain unnoticed if studying solely baseline (i.e., non-exercise) conditions. Although NKCA following IL-2 stimulation was lower at baseline and post-exercise in the children with ALL in remission compared to controls. In both groups, acute exercise induced a similar relative increase in unstimulated NKCA. Therefore, while further research is needed, exercise might be considered to improve NK cell function in children with ALL in remission.</p>
</sec>
</body>
<back>
<sec id="s6" sec-type="data-availability">
<title>Data availability statement</title>
<p>The gene data analyzed in this article have been deposited in the Gene Expression Omnibus. Gene expression GEO record: GSE272928 (<uri xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE272928">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE272928</uri>).</p>
</sec>
<sec id="s7" sec-type="ethics-statement">
<title>Ethics statement</title>
<p>The Institutional Review Board at the UC Irvine approved the study, and written, informed assent and consent were obtained from all participants and their legal guardians upon enrollment. The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation in this study was provided by the participants&#x2019; legal guardians/next of kin.</p>
</sec>
<sec id="s8" sec-type="author-contributions">
<title>Author contributions</title>
<p>AP-F: Writing &#x2013; original draft, Writing &#x2013; review &amp; editing, Formal analysis, Visualization. MP: Writing &#x2013; original draft, Writing &#x2013; review &amp; editing, Data curation, Formal analysis. FH: Writing &#x2013; review &amp; editing, Formal analysis, Visualization. DC: Writing &#x2013; review &amp; editing, Conceptualization, Investigation, Supervision. RB-Y: Writing &#x2013; review &amp; editing. AL: Writing &#x2013; review &amp; editing, Writing &#x2013; original draft. SR-A: Writing &#x2013; original draft, Writing &#x2013; review &amp; editing, Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Supervision.</p>
</sec>
<sec id="s9" sec-type="funding-information">
<title>Funding</title>
<p>The author(s) declare financial support was received for the research and/or publication of this article. This work was made possible through UC Irvine School of Medicine Faculty Grant (Radom-Aizik, PI), National Institutes of Health (NIH) grant #: NIH grant #: U01 TR002004 (REACH project), and through access to the following: the Genomics Research and Technology Hub (formerly Genomics High-Throughput Facility) Shared Resource of the Cancer Center Support Grant (P30CA-062203), the Single Cell Analysis Core shared resource of Complexity, Cooperation and Community in Cancer (U54CA217378), the Genomics-Bioinformatics Core of the Skin Biology Resource Based Center @ UCI (P30AR075047) at the University of California Irvine and NIH shared instrumentation grants 1S10OD010794-01 (PacBio RS), and 1S10OD021718-01 (HiSeq 4000). Research by AL is funded by Wereld Kanker Onderzoek Fonds (WKOF) as part of the World Cancer Research Fund International grant program (IIG_FULL_2021_007).</p>
</sec>
<ack>
<title>Acknowledgments</title>
<p>We thank Leonard Sender, MD, at the Children&#x2019;s Hospital of Orange County (CHOC), Orange, CA, for his assistance with evaluating and recruiting study participants; Ms. Annamarie Stehli, MPH, for her support with statistical analysis; and Mr. Hoang Pham, MSc, exercise physiologist, for conducting exercise assessments in the Pediatric Exercise and Genomics Research Center&#x2019;s Human Performance Laboratory.</p>
</ack>
<sec id="s10" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. All authors provided critical revisions and approved the final manuscript.</p>
</sec>
<sec id="s11" sec-type="ai-statement">
<title>Generative AI statement</title>
<p>The author(s) declare that no Generative AI was used in the creation of this manuscript.</p>
</sec>
<sec id="s12" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec id="s13" sec-type="supplementary-material">
<title>Supplementary material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fimmu.2025.1625437/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fimmu.2025.1625437/full#supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="Image1.jpeg" id="SF1" mimetype="image/jpeg">
<label>Supplementary Figure&#xa0;1</label>
<caption>
<p>Within-group comparison of gene expression analysis (i.e., post- vs. preexercise, separately in each group) showed gene pathways altered by exercise in children with acute lymphoblastic leukemia (ALL) in remission and controls (CONT). The blue color represents inhibition and orange activation, and the gray effect is not predicted.</p>
</caption>
</supplementary-material>
<supplementary-material xlink:href="Supplementaryfile1.xlsx" id="SM1" mimetype="application/vnd.openxmlformats-officedocument.spreadsheetml.sheet"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cheung</surname> <given-names>YT</given-names>
</name>
<name>
<surname>To</surname> <given-names>KK-W</given-names>
</name>
<name>
<surname>Hua</surname> <given-names>R</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>CP</given-names>
</name>
<name>
<surname>Chan</surname> <given-names>AS-Y</given-names>
</name>
<name>
<surname>Li</surname> <given-names>CK</given-names>
</name>
</person-group>. <article-title>Association of markers of inflammation on attention and neurobehavioral outcomes in survivors of childhood acute lymphoblastic leukemia</article-title>. <source>Front Oncol</source>. (<year>2023</year>) <volume>13</volume>:<elocation-id>1117096</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fonc.2023.1117096</pub-id>, PMID: <pub-id pub-id-type="pmid">37416531</pub-id></citation></ref>
<ref id="B2">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pui</surname> <given-names>CH</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>JJ</given-names>
</name>
<name>
<surname>Bhakta</surname> <given-names>N</given-names>
</name>
<name>
<surname>Rodriguez-Galindo</surname> <given-names>C</given-names>
</name>
</person-group>. <article-title>Global efforts toward the cure of childhood acute lymphoblastic leukaemia</article-title>. <source>Lancet Child Adolesc Health</source>. (<year>2018</year>) <volume>2</volume>:<page-range>440&#x2013;54</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/S2352-4642(18)30066-X</pub-id>, PMID: <pub-id pub-id-type="pmid">30169285</pub-id></citation></ref>
<ref id="B3">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morales</surname> <given-names>JS</given-names>
</name>
<name>
<surname>Valenzuela</surname> <given-names>PL</given-names>
</name>
<name>
<surname>Vel&#xe1;zquez-D&#xed;az</surname> <given-names>D</given-names>
</name>
<name>
<surname>Castillo-Garc&#xed;a</surname> <given-names>A</given-names>
</name>
<name>
<surname>Jim&#xe9;nez-Pav&#xf3;n</surname> <given-names>D</given-names>
</name>
<name>
<surname>Lucia</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Exercise and childhood cancer&#x2014;a historical review</article-title>. <source>Cancers (Basel)</source>. (<year>2022</year>) <volume>14</volume>:<page-range>1&#x2013;32</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/cancers14010082</pub-id>, PMID: <pub-id pub-id-type="pmid">35008246</pub-id></citation></ref>
<ref id="B4">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guilcher</surname> <given-names>GMT</given-names>
</name>
<name>
<surname>Rivard</surname> <given-names>L</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>JT</given-names>
</name>
<name>
<surname>Wright</surname> <given-names>NAM</given-names>
</name>
<name>
<surname>Anderson</surname> <given-names>L</given-names>
</name>
<name>
<surname>Eissa</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Immune function in childhood cancer survivors: a Children&#x2019;s Oncology Group review</article-title>. <source>Lancet Child Adolesc Health</source>. (<year>2021</year>) <volume>5</volume>:<page-range>284&#x2013;94</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/S2352-4642(20)30312-6</pub-id>, PMID: <pub-id pub-id-type="pmid">33600774</pub-id></citation></ref>
<ref id="B5">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dixon</surname> <given-names>SB</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Chow</surname> <given-names>EJ</given-names>
</name>
<name>
<surname>Oeffinger</surname> <given-names>KC</given-names>
</name>
<name>
<surname>Nathan</surname> <given-names>PC</given-names>
</name>
<name>
<surname>Howell</surname> <given-names>RM</given-names>
</name>
<etal/>
</person-group>. <article-title>Specific causes of excess late mortality and association with modifiable risk factors among survivors of childhood cancer: a report from the Childhood Cancer Survivor Study cohort</article-title>. <source>Lancet</source>. (<year>2023</year>) <volume>401</volume>:<page-range>1447&#x2013;57</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/S0140-6736(22)02471-0</pub-id>, PMID: <pub-id pub-id-type="pmid">37030315</pub-id></citation></ref>
<ref id="B6">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ariffin</surname> <given-names>H</given-names>
</name>
<name>
<surname>Azanan</surname> <given-names>MS</given-names>
</name>
<name>
<surname>Abd Ghafar</surname> <given-names>SS</given-names>
</name>
<name>
<surname>Oh</surname> <given-names>L</given-names>
</name>
<name>
<surname>Lau</surname> <given-names>KH</given-names>
</name>
<name>
<surname>Thirunavakarasu</surname> <given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Young adult survivors of childhood acute lymphoblastic leukemia show evidence of chronic inflammation and cellular aging</article-title>. <source>Cancer</source>. (<year>2017</year>) <volume>123</volume>:<page-range>4207&#x2013;14</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/cncr.30857</pub-id>, PMID: <pub-id pub-id-type="pmid">28654149</pub-id></citation></ref>
<ref id="B7">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cheung</surname> <given-names>YT</given-names>
</name>
<name>
<surname>Brinkman</surname> <given-names>TM</given-names>
</name>
<name>
<surname>Mulrooney</surname> <given-names>DA</given-names>
</name>
<name>
<surname>Mzayek</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>W</given-names>
</name>
<name>
<surname>Banerjee</surname> <given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>Impact of sleep, fatigue, and systemic inflammation on neurocognitive and behavioral outcomes in long-term survivors of childhood acute lymphoblastic leukemia</article-title>. <source>Cancer</source>. (<year>2017</year>) <volume>123</volume>:<page-range>3410&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/cncr.30742</pub-id>, PMID: <pub-id pub-id-type="pmid">28452142</pub-id></citation></ref>
<ref id="B8">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Daher</surname> <given-names>M</given-names>
</name>
<name>
<surname>Rezvani</surname> <given-names>K</given-names>
</name>
</person-group>. <article-title>Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering</article-title>. <source>Curr Opin Immunol</source>. (<year>2018</year>) <volume>51</volume>:<page-range>146&#x2013;53</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.coi.2018.03.013</pub-id>, PMID: <pub-id pub-id-type="pmid">29605760</pub-id></citation></ref>
<ref id="B9">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Handgretinger</surname> <given-names>R</given-names>
</name>
<name>
<surname>Lang</surname> <given-names>P</given-names>
</name>
<name>
<surname>Andr&#xe9;</surname> <given-names>MC</given-names>
</name>
</person-group>. <article-title>Exploitation of natural killer cells for the treatment of acute leukemia</article-title>. <source>Blood</source>. (<year>2016</year>) <volume>127</volume>:<page-range>3341&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1182/blood-2015-12-629055</pub-id>, PMID: <pub-id pub-id-type="pmid">27207791</pub-id></citation></ref>
<ref id="B10">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duault</surname> <given-names>C</given-names>
</name>
<name>
<surname>Kumar</surname> <given-names>A</given-names>
</name>
<name>
<surname>Khani</surname> <given-names>AT</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>SJ</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Activated natural killer cells predict poor clinical prognosis in high-risk B-and T-cell acute lymphoblastic leukemia</article-title>. <source>Blood</source>. (<year>2021</year>) <volume>138</volume>:<page-range>1465&#x2013;80</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1182/blood.2020009871</pub-id>, PMID: <pub-id pub-id-type="pmid">34077953</pub-id></citation></ref>
<ref id="B11">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Colomar-Carando</surname> <given-names>N</given-names>
</name>
<name>
<surname>Gauthier</surname> <given-names>L</given-names>
</name>
<name>
<surname>Merli</surname> <given-names>P</given-names>
</name>
<name>
<surname>Loiacono</surname> <given-names>F</given-names>
</name>
<name>
<surname>Canevali</surname> <given-names>P</given-names>
</name>
<name>
<surname>Falco</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Exploiting natural killer cell engagers to control pediatric B-cell precursor acute lymphoblastic leukemia</article-title>. <source>Cancer Immunol Res</source>. (<year>2022</year>) <volume>10</volume>:<fpage>291</fpage>&#x2013;<lpage>302</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1158/2326-6066.CIR-21-0843</pub-id>, PMID: <pub-id pub-id-type="pmid">35078821</pub-id></citation></ref>
<ref id="B12">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Valenzuela-V&#xe1;zquez</surname> <given-names>L</given-names>
</name>
<name>
<surname>Nu&#xf1;ez-Enriquez</surname> <given-names>JC</given-names>
</name>
<name>
<surname>S&#xe1;nchez-Herrera</surname> <given-names>J</given-names>
</name>
<name>
<surname>Medina-Sanson</surname> <given-names>A</given-names>
</name>
<name>
<surname>P&#xe9;rez-Saldivar</surname> <given-names>ML</given-names>
</name>
<name>
<surname>Jim&#xe9;nez-Hern&#xe1;ndez</surname> <given-names>E</given-names>
</name>
<etal/>
</person-group>. <article-title>NK cells with decreased expression of multiple activating receptors is a dominant phenotype in pediatric patients with acute lymphoblastic leukemia</article-title>. <source>Front Oncol</source>. (<year>2022</year>) <volume>12</volume>:<elocation-id>1023510</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fonc.2022.1023510</pub-id>, PMID: <pub-id pub-id-type="pmid">36419901</pub-id></citation></ref>
<ref id="B13">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mizia-Malarz</surname> <given-names>A</given-names>
</name>
<name>
<surname>Sobol-Milejska</surname> <given-names>G</given-names>
</name>
</person-group>. <article-title>NK cells as possible prognostic factor in childhood acute lymphoblastic leukemia</article-title>. <source>Dis Markers</source>. (<year>2019</year>) <volume>2019</volume>:<page-range>1&#x2013;4</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1155/2019/3596983</pub-id>, PMID: <pub-id pub-id-type="pmid">30719179</pub-id></citation></ref>
<ref id="B14">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shumock</surname> <given-names>SS</given-names>
</name>
<name>
<surname>Temple</surname> <given-names>WC</given-names>
</name>
<name>
<surname>Marinoff</surname> <given-names>A</given-names>
</name>
<name>
<surname>Aaronson</surname> <given-names>K</given-names>
</name>
<name>
<surname>Southworth</surname> <given-names>E</given-names>
</name>
<name>
<surname>Xirenayi</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Pre-and post-HSCT use of TKI therapy for fusion-driven B-ALL: A case series of five pediatric, adolescent and young adult patients</article-title>. <source>Cancer Rep</source>. (<year>2023</year>) <volume>6</volume>:<page-range>1&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/cnr2.1901</pub-id>, PMID: <pub-id pub-id-type="pmid">37933765</pub-id></citation></ref>
<ref id="B15">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krieg</surname> <given-names>S</given-names>
</name>
<name>
<surname>Ullrich</surname> <given-names>E</given-names>
</name>
</person-group>. <article-title>Novel immune modulators used in hematology: Impact on NK cells</article-title>. <source>Front Immunol</source>. (<year>2012</year>) <volume>3</volume>:<elocation-id>388</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2012.00388</pub-id>, PMID: <pub-id pub-id-type="pmid">23316191</pub-id></citation></ref>
<ref id="B16">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Damele</surname> <given-names>L</given-names>
</name>
<name>
<surname>Montaldo</surname> <given-names>E</given-names>
</name>
<name>
<surname>Moretta</surname> <given-names>L</given-names>
</name>
<name>
<surname>Vitale</surname> <given-names>C</given-names>
</name>
<name>
<surname>Mingari</surname> <given-names>MC</given-names>
</name>
</person-group>. <article-title>Effect of tyrosin kinase inhibitors on NK Cell and ILC3 development and function</article-title>. <source>Front Immunol</source>. (<year>2018</year>) <volume>9</volume>:<elocation-id>2433</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2018.02433</pub-id>, PMID: <pub-id pub-id-type="pmid">30405627</pub-id></citation></ref>
<ref id="B17">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fiuza-Luces</surname> <given-names>C</given-names>
</name>
<name>
<surname>Valenzuela</surname> <given-names>PL</given-names>
</name>
<name>
<surname>Gonz&#xe1;lez G&#xe1;lvez</surname> <given-names>B</given-names>
</name>
<name>
<surname>Ram&#xed;rez</surname> <given-names>M</given-names>
</name>
<name>
<surname>L&#xf3;pez-Soto</surname> <given-names>A</given-names>
</name>
<name>
<surname>Simpson</surname> <given-names>RJ</given-names>
</name>
<etal/>
</person-group>. <article-title>The effect of physical exercise on anticancer immunity</article-title>. <source>Nat Rev Immunol</source>. (<year>2023</year>) <volume>24</volume>:<page-range>282&#x2013;93</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41577-023-00943-0</pub-id>, PMID: <pub-id pub-id-type="pmid">37794239</pub-id></citation></ref>
<ref id="B18">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fiuza-Luces</surname> <given-names>C</given-names>
</name>
<name>
<surname>Valenzuela</surname> <given-names>PL</given-names>
</name>
<name>
<surname>Castillo-Garc&#xed;a</surname> <given-names>A</given-names>
</name>
<name>
<surname>Lucia</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>Exercise benefits meet cancer immunosurveillance: implications for immunotherapy</article-title>. <source>Trends Cancer</source>. (<year>2021</year>) <volume>7</volume>:<page-range>91&#x2013;3</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.trecan.2020.12.003</pub-id>, PMID: <pub-id pub-id-type="pmid">33358110</pub-id></citation></ref>
<ref id="B19">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>L&#xe4;hteenm&#xe4;ki Taalas</surname> <given-names>T</given-names>
</name>
<name>
<surname>J&#xe4;rvel&#xe4;</surname> <given-names>L</given-names>
</name>
<name>
<surname>Niinikoski</surname> <given-names>H</given-names>
</name>
<name>
<surname>Huurre</surname> <given-names>A</given-names>
</name>
<name>
<surname>Harila-Saari</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>Inflammatory biomarkers after an exercise intervention in childhood acute lymphoblastic leukemia survivors</article-title>. <source>EJHaem</source>. (<year>2022</year>) <volume>3</volume>:<page-range>1188&#x2013;200</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/jha2.588</pub-id>, PMID: <pub-id pub-id-type="pmid">36467791</pub-id></citation></ref>
<ref id="B20">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Timmons</surname> <given-names>BW</given-names>
</name>
</person-group>. <article-title>Paediatric exercise immunology: health and clinical applications running title: paediatric exercise immunology</article-title>. <source>Exerc Immunol Rev</source>. (<year>2005</year>) <volume>11</volume>:<page-range>108&#x2013;44</page-range>.</citation></ref>
<ref id="B21">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Timmons</surname> <given-names>BW</given-names>
</name>
<name>
<surname>Tarnopolsky</surname> <given-names>MA</given-names>
</name>
<name>
<surname>Bar-Or</surname> <given-names>O</given-names>
</name>
</person-group>. <article-title>Sex-based effects on the distribution of NK cell subsets in response to exercise and carbohydrate intake in adolescents</article-title>. <source>J Appl Physiol</source>. (<year>2006</year>) <volume>100</volume>:<page-range>1513&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1152/japplphysiol.01125.2005</pub-id>, PMID: <pub-id pub-id-type="pmid">16410379</pub-id></citation></ref>
<ref id="B22">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rumpf</surname> <given-names>C</given-names>
</name>
<name>
<surname>Proschinger</surname> <given-names>S</given-names>
</name>
<name>
<surname>Schenk</surname> <given-names>A</given-names>
</name>
<name>
<surname>Bloch</surname> <given-names>W</given-names>
</name>
<name>
<surname>Lampit</surname> <given-names>A</given-names>
</name>
<name>
<surname>Javelle</surname> <given-names>F</given-names>
</name>
<etal/>
</person-group>. <article-title>The effect of acute physical exercise on NK-cell cytolytic activity: A systematic review and meta-analysis</article-title>. <source>Sports Med</source>. (<year>2021</year>) <volume>51</volume>:<page-range>519&#x2013;30</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s40279-020-01402-9</pub-id>, PMID: <pub-id pub-id-type="pmid">33398798</pub-id></citation></ref>
<ref id="B23">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sanford</surname> <given-names>JA</given-names>
</name>
<name>
<surname>Nogiec</surname> <given-names>CD</given-names>
</name>
<name>
<surname>Lindholm</surname> <given-names>ME</given-names>
</name>
<name>
<surname>Adkins</surname> <given-names>JN</given-names>
</name>
<name>
<surname>Amar</surname> <given-names>D</given-names>
</name>
<name>
<surname>Dasari</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Molecular transducers of physical activity consortium (MoTrPAC): mapping the dynamic responses to exercise</article-title>. <source>Cell</source>. (<year>2020</year>) <volume>181</volume>:<page-range>1464&#x2013;74</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.cell.2020.06.004</pub-id>, PMID: <pub-id pub-id-type="pmid">32589957</pub-id></citation></ref>
<ref id="B24">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Radom-Aizik</surname> <given-names>S</given-names>
</name>
<name>
<surname>Zaldivar</surname> <given-names>F</given-names>
</name>
<name>
<surname>Haddad</surname> <given-names>F</given-names>
</name>
<name>
<surname>Cooper</surname> <given-names>DM</given-names>
</name>
</person-group>. <article-title>Impact of brief exercise on peripheral blood NK cell gene and microRNA expression in young adults</article-title>. <source>J Appl Physiol</source>. (<year>2013</year>) <volume>114</volume>:<page-range>628&#x2013;36</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1152/japplphysiol.01341.2012</pub-id>, PMID: <pub-id pub-id-type="pmid">23288554</pub-id></citation></ref>
<ref id="B25">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Batatinha</surname> <given-names>H</given-names>
</name>
<name>
<surname>Diak</surname> <given-names>DM</given-names>
</name>
<name>
<surname>Niemiro</surname> <given-names>GM</given-names>
</name>
<name>
<surname>Baker</surname> <given-names>FL</given-names>
</name>
<name>
<surname>Smith</surname> <given-names>KA</given-names>
</name>
<name>
<surname>Z&#xfa;&#xf1;iga</surname> <given-names>TM</given-names>
</name>
<etal/>
</person-group>. <article-title>Human lymphocytes mobilized with exercise have an anti-tumor transcriptomic profile and exert enhanced graft-versus-leukemia effects in xenogeneic mice</article-title>. <source>Front Immunol</source>. (<year>2023</year>) <volume>14</volume>:<elocation-id>1067369</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2023.1067369</pub-id>, PMID: <pub-id pub-id-type="pmid">37077913</pub-id></citation></ref>
<ref id="B26">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Radom-Aizik</surname> <given-names>S</given-names>
</name>
<name>
<surname>Zaldivar</surname> <given-names>F</given-names>
</name>
<name>
<surname>Leu</surname> <given-names>SY</given-names>
</name>
<name>
<surname>Cooper</surname> <given-names>DM</given-names>
</name>
</person-group>. <article-title>Brief bout of exercise alters gene expression in peripheral blood mononuclear cells of early- and late-pubertal males</article-title>. <source>Pediatr Res</source>. (<year>2009</year>) <volume>107</volume>:<page-range>168&#x2013;75</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1203/PDR.0b013e3181993473</pub-id>, PMID: <pub-id pub-id-type="pmid">19127215</pub-id></citation></ref>
<ref id="B27">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Radom-Aizik</surname> <given-names>S</given-names>
</name>
<name>
<surname>Zaldivar</surname> <given-names>F</given-names>
</name>
<name>
<surname>Leu</surname> <given-names>SY</given-names>
</name>
<name>
<surname>Cooper</surname> <given-names>DM</given-names>
</name>
</person-group>. <article-title>A brief bout of exercise alters gene expression and distinct gene pathways in peripheral blood mononuclear cells of early- and late-pubertal females</article-title>. <source>J Appl Physiol</source>. (<year>2009</year>) <volume>107</volume>:<page-range>168&#x2013;75</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1152/japplphysiol.00121.2009</pub-id>, PMID: <pub-id pub-id-type="pmid">19407257</pub-id></citation></ref>
<ref id="B28">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marumo</surname> <given-names>K</given-names>
</name>
<name>
<surname>Ueno</surname> <given-names>M</given-names>
</name>
<name>
<surname>Baba</surname> <given-names>S</given-names>
</name>
<name>
<surname>Takazi</surname> <given-names>H</given-names>
</name>
</person-group>. <article-title>Augmentation of cell-mediated cytotoxicity against renal carcinoma cells by recombinant interleukin 2</article-title>. <source>Urology</source>. (<year>1987</year>) <volume>30</volume>:<page-range>327&#x2013;32</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/0090-4295(87)90294-9</pub-id>, PMID: <pub-id pub-id-type="pmid">3116737</pub-id></citation></ref>
<ref id="B29">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kr&#xe4;mer</surname> <given-names>A</given-names>
</name>
<name>
<surname>Green</surname> <given-names>J</given-names>
</name>
<name>
<surname>Pollard</surname> <given-names>J</given-names>
</name>
<name>
<surname>Tugendreich</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>Causal analysis approaches in ingenuity pathway analysis</article-title>. <source>Bioinformatics</source>. (<year>2014</year>) <volume>30</volume>:<page-range>523&#x2013;30</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/bioinformatics/btt703</pub-id>, PMID: <pub-id pub-id-type="pmid">24336805</pub-id></citation></ref>
<ref id="B30">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Altm&#xe4;e</surname> <given-names>S</given-names>
</name>
<name>
<surname>Plaza-Florido</surname> <given-names>A</given-names>
</name>
<name>
<surname>Esteban</surname> <given-names>FJ</given-names>
</name>
<name>
<surname>Anguita-Ruiz</surname> <given-names>A</given-names>
</name>
<name>
<surname>Krjut&#x161;kov</surname> <given-names>K</given-names>
</name>
<name>
<surname>Katayama</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Effects of exercise on whole-blood transcriptome profile in children with overweight/obesity</article-title>. <source>Am J Hum Biol</source>. (<year>2023</year>). doi:&#xa0;<pub-id pub-id-type="doi">10.1002/ajhb.23983</pub-id>, PMID: <pub-id pub-id-type="pmid">37715654</pub-id></citation></ref>
<ref id="B31">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Capellino</surname> <given-names>S</given-names>
</name>
<name>
<surname>Claus</surname> <given-names>M</given-names>
</name>
<name>
<surname>Watzl</surname> <given-names>C</given-names>
</name>
</person-group>. <article-title>Regulation of natural killer cell activity by glucocorticoids, serotonin, dopamine, and epinephrine</article-title>. <source>Cell Mol Immunol</source>. (<year>2020</year>) <volume>17</volume>:<page-range>705&#x2013;11</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41423-020-0477-9</pub-id>, PMID: <pub-id pub-id-type="pmid">32503998</pub-id></citation></ref>
<ref id="B32">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>KS</given-names>
</name>
<name>
<surname>Frank</surname> <given-names>DA</given-names>
</name>
<name>
<surname>Ritz</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>Interleukin-2 enhances the response of natural killer cells to interleukin-12 through up-regulation of the interleukin-12 receptor and STAT4</article-title>. <source>Blood</source>. (<year>2000</year>) <volume>95</volume>:<page-range>3183&#x2013;90</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1182/blood.V95.10.3183</pub-id>, PMID: <pub-id pub-id-type="pmid">10807786</pub-id></citation></ref>
<ref id="B33">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mace</surname> <given-names>EM</given-names>
</name>
</person-group>. <article-title>Phosphoinositide-3-kinase signaling in human natural killer cells: New insights from primary immunodeficiency</article-title>. <source>Front Immunol</source>. (<year>2018</year>) <volume>9</volume>:<elocation-id>445</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2018.00445</pub-id>, PMID: <pub-id pub-id-type="pmid">29563913</pub-id></citation></ref>
<ref id="B34">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gotthardt</surname> <given-names>D</given-names>
</name>
<name>
<surname>Trifinopoulos</surname> <given-names>J</given-names>
</name>
<name>
<surname>Sexl</surname> <given-names>V</given-names>
</name>
<name>
<surname>Putz</surname> <given-names>EM</given-names>
</name>
</person-group>. <article-title>JAK/STAT cytokine signaling at the crossroad of NK cell development and maturation</article-title>. <source>Front Immunol</source>. (<year>2019</year>) <volume>10</volume>:<elocation-id>2590</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2019.02590</pub-id>, PMID: <pub-id pub-id-type="pmid">31781102</pub-id></citation></ref>
<ref id="B35">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wahlen</surname> <given-names>S</given-names>
</name>
<name>
<surname>Matthijssens</surname> <given-names>F</given-names>
</name>
<name>
<surname>Van Loocke</surname> <given-names>W</given-names>
</name>
<name>
<surname>Taveirne</surname> <given-names>S</given-names>
</name>
<name>
<surname>Kiekens</surname> <given-names>L</given-names>
</name>
<name>
<surname>Persyn</surname> <given-names>E</given-names>
</name>
<etal/>
</person-group>. <article-title>The transcription factor RUNX2 drives the generation of human NK cells and promotes tissue residency</article-title>. <source>Elife</source>. (<year>2022</year>) <volume>11</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.7554/ELIFE.80320</pub-id>, PMID: <pub-id pub-id-type="pmid">35793229</pub-id></citation></ref>
<ref id="B36">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matthijssens</surname> <given-names>F</given-names>
</name>
<name>
<surname>Sharma</surname> <given-names>ND</given-names>
</name>
<name>
<surname>Nysus</surname> <given-names>M</given-names>
</name>
<name>
<surname>Nickl</surname> <given-names>CK</given-names>
</name>
<name>
<surname>Kang</surname> <given-names>H</given-names>
</name>
<name>
<surname>Perez</surname> <given-names>DR</given-names>
</name>
<etal/>
</person-group>. <article-title>RUNX2 regulates leukemic cell metabolism and chemotaxis in high-risk T cell acute lymphoblastic leukemia</article-title>. <source>J Clin Invest</source>. (<year>2021</year>) <volume>131</volume>:<page-range>1&#x2013;19</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1172/JCI141566</pub-id>, PMID: <pub-id pub-id-type="pmid">33555272</pub-id></citation></ref>
<ref id="B37">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>D&#x2019;Amico</surname> <given-names>S</given-names>
</name>
<name>
<surname>Tempora</surname> <given-names>P</given-names>
</name>
<name>
<surname>Melaiu</surname> <given-names>O</given-names>
</name>
<name>
<surname>Lucarini</surname> <given-names>V</given-names>
</name>
<name>
<surname>Cifaldi</surname> <given-names>L</given-names>
</name>
<name>
<surname>Locatelli</surname> <given-names>F</given-names>
</name>
<etal/>
</person-group>. <article-title>Targeting the antigen processing and presentation pathway to overcome resistance to immune checkpoint therapy</article-title>. <source>Front Immunol</source>. (<year>2022</year>) <volume>13</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2022.948297</pub-id>, PMID: <pub-id pub-id-type="pmid">35936007</pub-id></citation></ref>
<ref id="B38">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shen</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Guan</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Hummel</surname> <given-names>JJ</given-names>
</name>
<name>
<surname>Shyu</surname> <given-names>CR</given-names>
</name>
<name>
<surname>Mitchem</surname> <given-names>JB</given-names>
</name>
</person-group>. <article-title>Immunogenomic pathways associated with cytotoxic lymphocyte infiltration and survival in colorectal cancer</article-title>. <source>BMC Cancer</source>. (<year>2020</year>) <volume>20</volume>:<page-range>1&#x2013;10</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s12885-020-6513-4</pub-id>, PMID: <pub-id pub-id-type="pmid">32059711</pub-id></citation></ref>
<ref id="B39">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Steiner</surname> <given-names>J</given-names>
</name>
<name>
<surname>Marquardt</surname> <given-names>N</given-names>
</name>
<name>
<surname>Pauls</surname> <given-names>I</given-names>
</name>
<name>
<surname>Schiltz</surname> <given-names>K</given-names>
</name>
<name>
<surname>Rahmoune</surname> <given-names>H</given-names>
</name>
<name>
<surname>Bahn</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Human CD8 + T cells and NK cells express and secrete S100B upon stimulation</article-title>. <source>Brain Behav Immun</source>. (<year>2011</year>) <volume>25</volume>:<page-range>1233&#x2013;41</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.bbi.2011.03.015</pub-id>, PMID: <pub-id pub-id-type="pmid">21447379</pub-id></citation></ref>
<ref id="B40">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hua</surname> <given-names>X</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>H</given-names>
</name>
<name>
<surname>Jia</surname> <given-names>J</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>S</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zhu</surname> <given-names>X</given-names>
</name>
</person-group>. <article-title>Roles of S100 family members in drug resistance in tumors: Status and prospects</article-title>. <source>Biomed Pharmacother</source>. (<year>2020</year>) <volume>127</volume>:<page-range>1&#x2013;14</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.biopha.2020.110156</pub-id>, PMID: <pub-id pub-id-type="pmid">32335300</pub-id></citation></ref>
<ref id="B41">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mondet</surname> <given-names>J</given-names>
</name>
<name>
<surname>Chevalier</surname> <given-names>S</given-names>
</name>
<name>
<surname>Mossuz</surname> <given-names>P</given-names>
</name>
</person-group>. <article-title>Pathogenic roles of S100A8 and S100A9 proteins in acute myeloid and lymphoid leukemia: Clinical and therapeutic impacts</article-title>. <source>Molecules</source>. (<year>2021</year>) <volume>26</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/molecules26051323</pub-id>, PMID: <pub-id pub-id-type="pmid">33801279</pub-id></citation></ref>
<ref id="B42">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brix</surname> <given-names>N</given-names>
</name>
<name>
<surname>Glerup</surname> <given-names>M</given-names>
</name>
<name>
<surname>Foell</surname> <given-names>D</given-names>
</name>
<name>
<surname>Kessel</surname> <given-names>C</given-names>
</name>
<name>
<surname>Wittkowski</surname> <given-names>H</given-names>
</name>
<name>
<surname>Berntson</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Inflammatory biomarkers can differentiate acute lymphoblastic leukemia with arthropathy from juvenile idiopathic arthritis better than standard blood tests</article-title>. <source>J Pediatr</source>. (<year>2023</year>) <volume>258</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jpeds.2023.113406</pub-id>, PMID: <pub-id pub-id-type="pmid">37023943</pub-id></citation></ref>
<ref id="B43">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singh</surname> <given-names>P</given-names>
</name>
<name>
<surname>Ali</surname> <given-names>SA</given-names>
</name>
</person-group>. <article-title>Multifunctional role of S100 protein family in the immune system: an update</article-title>. <source>Cells</source>. (<year>2022</year>) <volume>11</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/cells11152274</pub-id>, PMID: <pub-id pub-id-type="pmid">35892571</pub-id></citation></ref>
<ref id="B44">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gonzalez</surname> <given-names>LL</given-names>
</name>
<name>
<surname>Garrie</surname> <given-names>K</given-names>
</name>
<name>
<surname>Turner</surname> <given-names>MD</given-names>
</name>
</person-group>. <article-title>Role of S100 proteins in health and disease</article-title>. <source>Biochim Biophys Acta Mol Cell Res</source>. (<year>2020</year>) <volume>1867</volume>:<page-range>1&#x2013;16</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.bbamcr.2020.118677</pub-id>, PMID: <pub-id pub-id-type="pmid">32057918</pub-id></citation></ref>
<ref id="B45">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Narumi</surname> <given-names>K</given-names>
</name>
<name>
<surname>Miyakawa</surname> <given-names>R</given-names>
</name>
<name>
<surname>Ueda</surname> <given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Proinflammatory proteins S100A8/S100A9 activate NK cells via interaction with RAGE</article-title>. <source>J Immunol</source>. (<year>2015</year>) <volume>194</volume>:<page-range>5539&#x2013;48</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.4049/jimmunol.1402301</pub-id>, PMID: <pub-id pub-id-type="pmid">25911757</pub-id></citation></ref>
<ref id="B46">
<label>46</label>
<citation citation-type="web">
<person-group person-group-type="author">
<name>
<surname>Somanchi</surname> <given-names>SS</given-names>
</name>
</person-group>. <source>Natural Killer Cells: Methods and Protocols</source>. <publisher-loc>Humana New York, NY</publisher-loc>. (<year>2016</year>). <page-range>1&#x2013;365</page-range> p. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/978-1-4939-3684-7</pub-id>
</citation></ref>
<ref id="B47">
<label>47</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname> <given-names>X</given-names>
</name>
<name>
<surname>Friedmann</surname> <given-names>KS</given-names>
</name>
<name>
<surname>Lyrmann</surname> <given-names>H</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Schoppmeyer</surname> <given-names>R</given-names>
</name>
<name>
<surname>Kn&#xf6;rck</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>A calcium optimum for cytotoxic T lymphocyte and natural killer cell cytotoxicity</article-title>. <source>J Physiol</source>. (<year>2018</year>) <volume>596</volume>:<page-range>2681&#x2013;98</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1113/JP274964</pub-id>, PMID: <pub-id pub-id-type="pmid">29368348</pub-id></citation></ref>
<ref id="B48">
<label>48</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname> <given-names>X-Y</given-names>
</name>
<name>
<surname>Jin</surname> <given-names>J</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Li</surname> <given-names>P</given-names>
</name>
<name>
<surname>Xue</surname> <given-names>J-W</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>X-J</given-names>
</name>
<etal/>
</person-group>. <article-title>Expression and clinical significance profile analysis of S100 family members in human acute myeloid leukemia</article-title>. <source>Eur Rev Med Pharmacol Sci</source>. (<year>2020</year>) <volume>24</volume>:<page-range>7324&#x2013;34</page-range>., PMID: <pub-id pub-id-type="pmid">32706071</pub-id></citation></ref>
<ref id="B49">
<label>49</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brix</surname> <given-names>N</given-names>
</name>
<name>
<surname>Kessel</surname> <given-names>C</given-names>
</name>
<name>
<surname>Foell</surname> <given-names>D</given-names>
</name>
<name>
<surname>Hasle</surname> <given-names>H</given-names>
</name>
<name>
<surname>Albertsen</surname> <given-names>BK</given-names>
</name>
<name>
<surname>Bruun</surname> <given-names>NH</given-names>
</name>
<etal/>
</person-group>. <article-title>Phagocyte-related S100 proteins and cytokines in acute lymphoblastic leukemia and their prognostic value</article-title>. <source>Leuk Lymphoma</source>. (<year>2023</year>) <volume>64</volume>:<page-range>981&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1080/10428194.2023.2193855</pub-id>, PMID: <pub-id pub-id-type="pmid">37066963</pub-id></citation></ref>
<ref id="B50">
<label>50</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deguchi</surname> <given-names>A</given-names>
</name>
<name>
<surname>Maru</surname> <given-names>Y</given-names>
</name>
</person-group>. <article-title>S100A8 as a potential therapeutic target for cancer metastasis</article-title>. <source>Cancer Sci</source>. (<year>2024</year>) <volume>116</volume>:<page-range>322&#x2013;328</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/cas.16407</pub-id>, PMID: <pub-id pub-id-type="pmid">39581861</pub-id></citation></ref>
<ref id="B51">
<label>51</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Colonna</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>Trems in the immune system and beyond</article-title>. <source>Nat Rev Immunol</source>. (<year>2003</year>) <volume>3</volume>:<page-range>445&#x2013;53</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nri1106</pub-id>, PMID: <pub-id pub-id-type="pmid">12776204</pub-id></citation></ref>
<ref id="B52">
<label>52</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Colonna</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>The biology of TREM receptors</article-title>. <source>Nat Rev Immunol</source>. (<year>2023</year>) <volume>23</volume>:<page-range>580&#x2013;94</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41577-023-00837-1</pub-id>, PMID: <pub-id pub-id-type="pmid">36750615</pub-id></citation></ref>
<ref id="B53">
<label>53</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ajith</surname> <given-names>A</given-names>
</name>
<name>
<surname>Mamouni</surname> <given-names>K</given-names>
</name>
<name>
<surname>Horuzsko</surname> <given-names>DD</given-names>
</name>
<name>
<surname>Musa</surname> <given-names>A</given-names>
</name>
<name>
<surname>Dzutsev</surname> <given-names>AK</given-names>
</name>
<name>
<surname>Fang</surname> <given-names>JR</given-names>
</name>
<etal/>
</person-group>. <article-title>Targeting TREM1 augments antitumor T cell immunity by inhibiting myeloid-derived suppressor cells and restraining anti&#x2013;PD-1 resistance</article-title>. <source>J Clin Invest</source>. (<year>2023</year>) <volume>133</volume>:<page-range>1&#x2013;18</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1172/JCI167951</pub-id>, PMID: <pub-id pub-id-type="pmid">37651197</pub-id></citation></ref>
<ref id="B54">
<label>54</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Patterson</surname> <given-names>SL</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>S</given-names>
</name>
<name>
<surname>Rychkov</surname> <given-names>D</given-names>
</name>
<name>
<surname>Katz</surname> <given-names>P</given-names>
</name>
<name>
<surname>Tsitsiklis</surname> <given-names>A</given-names>
</name>
<name>
<surname>Nakamura</surname> <given-names>MC</given-names>
</name>
<etal/>
</person-group>. <article-title>Physical activity associates with lower systemic inflammatory gene expression in rheumatoid arthritis</article-title>. <source>J Rheumatol</source>. (<year>2022</year>) <volume>49</volume>:<page-range>1320&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.3899/jrheum.220050</pub-id>, PMID: <pub-id pub-id-type="pmid">35777820</pub-id></citation></ref>
<ref id="B55">
<label>55</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dopheide</surname> <given-names>JF</given-names>
</name>
<name>
<surname>Scheer</surname> <given-names>M</given-names>
</name>
<name>
<surname>Doppler</surname> <given-names>C</given-names>
</name>
<name>
<surname>Obst</surname> <given-names>V</given-names>
</name>
<name>
<surname>Stein</surname> <given-names>P</given-names>
</name>
<name>
<surname>Vosseler</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Change of walking distance in intermittent claudication: impact on inflammation, oxidative stress and mononuclear cells: a pilot study</article-title>. <source>Clin Res Cardiol</source>. (<year>2015</year>) <volume>104</volume>:<page-range>751&#x2013;63</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00392-015-0840-5</pub-id>, PMID: <pub-id pub-id-type="pmid">25772524</pub-id></citation></ref>
<ref id="B56">
<label>56</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mantovani</surname> <given-names>A</given-names>
</name>
<name>
<surname>Dinarello</surname> <given-names>CA</given-names>
</name>
<name>
<surname>Molgora</surname> <given-names>M</given-names>
</name>
<name>
<surname>Garlanda</surname> <given-names>C</given-names>
</name>
</person-group>. <article-title>Interleukin-1 and related cytokines in the regulation of inflammation and immunity</article-title>. <source>Immunity</source>. (<year>2019</year>) <volume>50</volume>:<page-range>778&#x2013;95</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.immuni.2019.03.012</pub-id>, PMID: <pub-id pub-id-type="pmid">30995499</pub-id></citation></ref>
<ref id="B57">
<label>57</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fitter</surname> <given-names>S</given-names>
</name>
<name>
<surname>Bradey</surname> <given-names>AL</given-names>
</name>
<name>
<surname>Kok</surname> <given-names>CH</given-names>
</name>
<name>
<surname>Noll</surname> <given-names>JE</given-names>
</name>
<name>
<surname>Wilczek</surname> <given-names>VJ</given-names>
</name>
<name>
<surname>Venn</surname> <given-names>NC</given-names>
</name>
<etal/>
</person-group>. <article-title>CKLF and IL1B transcript levels at diagnosis are predictive of relapse in children with pre-B-cell acute lymphoblastic leukaemia</article-title>. <source>Br J Haematol</source>. (<year>2021</year>) <volume>193</volume>:<page-range>171&#x2013;5</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/bjh.17161</pub-id>, PMID: <pub-id pub-id-type="pmid">33620089</pub-id></citation></ref>
<ref id="B58">
<label>58</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gjevestad</surname> <given-names>GO</given-names>
</name>
<name>
<surname>Holven</surname> <given-names>KB</given-names>
</name>
<name>
<surname>Ulven</surname> <given-names>SM</given-names>
</name>
</person-group>. <article-title>Effects of exercise on gene expression of inflammatory markers in human peripheral blood cells: A systematic review</article-title>. <source>Curr Cardiovasc Risk Rep</source>. (<year>2015</year>) <volume>9</volume>:<page-range>1&#x2013;17</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s12170-015-0463-4</pub-id>, PMID: <pub-id pub-id-type="pmid">26005511</pub-id></citation></ref>
<ref id="B59">
<label>59</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moldoveanu</surname> <given-names>AI</given-names>
</name>
<name>
<surname>Shephard</surname> <given-names>RJ</given-names>
</name>
<name>
<surname>Shek</surname> <given-names>PN</given-names>
</name>
</person-group>. <article-title>Exercise elevates plasma levels but not gene expression of IL-1, IL-6, and TNF-in blood mononuclear cells</article-title>. <source>J Appl Physiol</source>. (<year>2000</year>) <volume>89</volume>:<page-range>1499&#x2013;504</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1152/jappl.2000.89.4.1499</pub-id>, PMID: <pub-id pub-id-type="pmid">11007588</pub-id></citation></ref>
<ref id="B60">
<label>60</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tufa</surname> <given-names>DM</given-names>
</name>
<name>
<surname>Ahmad</surname> <given-names>F</given-names>
</name>
<name>
<surname>Chatterjee</surname> <given-names>D</given-names>
</name>
<name>
<surname>Ahrenstorf</surname> <given-names>G</given-names>
</name>
<name>
<surname>Schmidt</surname> <given-names>RE</given-names>
</name>
<name>
<surname>Jacobs</surname> <given-names>R</given-names>
</name>
</person-group>. <article-title>IL-1&#x3b2; limits the extent of human 6-sulfo LacNAc dendritic cell (slanDC)-mediated NK cell activation and regulates CD95-induced apoptosis</article-title>. <source>Cell Mol Immunol</source>. (<year>2017</year>) <volume>14</volume>:<page-range>976&#x2013;85</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/cmi.2016.17</pub-id>, PMID: <pub-id pub-id-type="pmid">27086951</pub-id></citation></ref>
<ref id="B61">
<label>61</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shakhar</surname> <given-names>G</given-names>
</name>
<name>
<surname>Abudarham</surname> <given-names>N</given-names>
</name>
<name>
<surname>Melamed</surname> <given-names>R</given-names>
</name>
<name>
<surname>Schwartz</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Rosenne</surname> <given-names>E</given-names>
</name>
<name>
<surname>Ben-Eliyahu</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>Amelioration of operation-induced suppression of marginating pulmonary NK activity using poly IC: A potential approach to reduce postoperative metastasis</article-title>. <source>Ann Surg Oncol</source>. (<year>2007</year>) <volume>14</volume>:<page-range>841&#x2013;52</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1245/s10434-006-9078-9</pub-id>, PMID: <pub-id pub-id-type="pmid">17091332</pub-id></citation></ref>
<ref id="B62">
<label>62</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baysoy</surname> <given-names>A</given-names>
</name>
<name>
<surname>Bai</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Satija</surname> <given-names>R</given-names>
</name>
<name>
<surname>Fan</surname> <given-names>R</given-names>
</name>
</person-group>. <article-title>The technological landscape and applications of single-cell multi-omics</article-title>. <source>Nat Rev Mol Cell Biol</source>. (<year>2023</year>) <volume>24</volume>:<fpage>695</fpage>&#x2013;<lpage>713</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41580-023-00615-w</pub-id>, PMID: <pub-id pub-id-type="pmid">37280296</pub-id></citation></ref>
<ref id="B63">
<label>63</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Plaza-Florido</surname> <given-names>A</given-names>
</name>
<name>
<surname>Lucia</surname> <given-names>A</given-names>
</name>
<name>
<surname>Radom-Aizik</surname> <given-names>S</given-names>
</name>
<name>
<surname>Fiuza-Luces</surname> <given-names>C</given-names>
</name>
</person-group>. <article-title>Anticancer effects of exercise: Insights from single-cell analysis</article-title>. <source>J Sport Health Sci</source>. (<year>2024</year>) <volume>13</volume>:<page-range>676&#x2013;678</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jshs.2024.01.008</pub-id>, PMID: <pub-id pub-id-type="pmid">38266673</pub-id></citation></ref>
<ref id="B64">
<label>64</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Plaza-Florido</surname> <given-names>A</given-names>
</name>
<name>
<surname>Lucia</surname> <given-names>A</given-names>
</name>
<name>
<surname>Radom-Aizik</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>Advancing pediatric exercise research: A focus on immunomics and cutting-edge technologies</article-title>. <source>J Sport Health Sci</source>. (<year>2023</year>) <volume>13</volume>:<page-range>679&#x2013;81</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jshs.2023.09.011</pub-id>, PMID: <pub-id pub-id-type="pmid">37788789</pub-id></citation></ref>
<ref id="B65">
<label>65</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Plaza-Florido</surname> <given-names>A</given-names>
</name>
<name>
<surname>P&#xe9;rez-Prieto</surname> <given-names>I</given-names>
</name>
<name>
<surname>Molina-Garcia</surname> <given-names>P</given-names>
</name>
<name>
<surname>Radom-Aizik</surname> <given-names>S</given-names>
</name>
<name>
<surname>Ortega</surname> <given-names>FB</given-names>
</name>
<name>
<surname>Altm&#xe4;e</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>Transcriptional and epigenetic response to sedentary behavior and physical activity in children and adolescents: A systematic review</article-title>. <source>Front Pediatr</source>. (<year>2022</year>) <volume>10</volume>:<fpage>1</fpage>&#x2013;<lpage>14</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fped.2022.917152</pub-id>, PMID: <pub-id pub-id-type="pmid">35813370</pub-id></citation></ref>
<ref id="B66">
<label>66</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Murphy</surname> <given-names>JM</given-names>
</name>
<name>
<surname>Rodriguez</surname> <given-names>YAR</given-names>
</name>
<name>
<surname>Jeong</surname> <given-names>K</given-names>
</name>
<name>
<surname>Ahn</surname> <given-names>EYE</given-names>
</name>
<name>
<surname>Lim</surname> <given-names>STS</given-names>
</name>
</person-group>. <article-title>Targeting focal adhesion kinase in cancer cells and the tumor microenvironment</article-title>. <source>Exp Mol Med</source>. (<year>2020</year>) <volume>52</volume>:<page-range>877&#x2013;86</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s12276-020-0447-4</pub-id>, PMID: <pub-id pub-id-type="pmid">32514188</pub-id></citation></ref>
<ref id="B67">
<label>67</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Noh</surname> <given-names>JY</given-names>
</name>
<name>
<surname>Yoon</surname> <given-names>SR</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>TD</given-names>
</name>
<name>
<surname>Choi</surname> <given-names>I</given-names>
</name>
<name>
<surname>Jung</surname> <given-names>H</given-names>
</name>
</person-group>. <article-title>Toll-like receptors in natural killer cells and their application for immunotherapy</article-title>. <source>J Immunol Res</source>. (<year>2020</year>) <volume>2020</volume>:<page-range>1&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1155/2020/2045860</pub-id>, PMID: <pub-id pub-id-type="pmid">32377528</pub-id></citation></ref>
<ref id="B68">
<label>68</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Turnquist</surname> <given-names>C</given-names>
</name>
<name>
<surname>Ryan</surname> <given-names>BM</given-names>
</name>
<name>
<surname>Horikawa</surname> <given-names>I</given-names>
</name>
<name>
<surname>Harris</surname> <given-names>BT</given-names>
</name>
<name>
<surname>Harris</surname> <given-names>CC</given-names>
</name>
</person-group>. <article-title>Cytokine storms in cancer and COVID-19</article-title>. <source>Cancer Cell</source>. (<year>2020</year>) <volume>38</volume>:<fpage>598</fpage>&#x2013;<lpage>601</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ccell.2020.09.019</pub-id>, PMID: <pub-id pub-id-type="pmid">33038939</pub-id></citation></ref>
<ref id="B69">
<label>69</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rodrigues</surname> <given-names>MC</given-names>
</name>
<name>
<surname>Morais</surname> <given-names>JAV</given-names>
</name>
<name>
<surname>Ganassin</surname> <given-names>R</given-names>
</name>
<name>
<surname>Oliveira</surname> <given-names>GRT</given-names>
</name>
<name>
<surname>Costa</surname> <given-names>FC</given-names>
</name>
<name>
<surname>Morais</surname> <given-names>AAC</given-names>
</name>
<etal/>
</person-group>. <article-title>An overview on immunogenic cell death in cancer biology and therapy</article-title>. <source>Pharmaceutics</source>. (<year>2022</year>) <volume>14</volume>:<page-range>1&#x2013;17</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/pharmaceutics14081564</pub-id>, PMID: <pub-id pub-id-type="pmid">36015189</pub-id></citation></ref>
<ref id="B70">
<label>70</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Selheim</surname> <given-names>F</given-names>
</name>
<name>
<surname>Aaseb&#xf8;</surname> <given-names>E</given-names>
</name>
<name>
<surname>Ribas</surname> <given-names>C</given-names>
</name>
<name>
<surname>Aragay</surname> <given-names>AM</given-names>
</name>
</person-group>. <article-title>An overview on G protein-coupled receptor-induced signal transduction in acute myeloid leukemia</article-title>. <source>Curr Med Chem</source>. (<year>2019</year>) <volume>26</volume>:<page-range>5293&#x2013;316</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2174/0929867326666190429153247</pub-id>, PMID: <pub-id pub-id-type="pmid">31032748</pub-id></citation></ref>
</ref-list>
</back>
</article>